Publications
2026
Scholarly publications
Rijke, N., Yamout, B. I., Saylor, D., Nonino, F., Filippini, G., Piggott, T., Laurson-Doube, J., Amato, L., Banerjee, T. K., Costello, K., Giovane, C. D., De Stefano, N., Abkari, N. E., Giovannoni, G., Hartung, H. P., Helme, A., Mantel-Teeuwisse, A., Prato Chichiraldi, A., Ali Sahraian, M., ... Schünemann, H. (2026). Recommendations for the use of off-label rituximab for the treatment of multiple sclerosis in low-resource settings. Multiple Sclerosis and Related Disorders, 105, Article 106878. [DOI]
2025
Scholarly publications
Jacobs, T. G., Ooms, G. I., Mantel-Teeuwisse, A. K., & Suleman, F. (2025). Commentary: Pediatric HIV Treatment: Nurturing Access Through Health Facility Availability and Stock-out Monitoring. The Pediatric Infectious Disease Journal, 44(8), 785-786. [DOI]
Lambert, M., van Dijk, L., Benko, R., Llor, C., Lykkegaard, J., Mantel-Teeuwisse, A. K., Pont, L., & Taxis, K. (2025). The role of the community pharmacist in antibiotic use - a commentary on current status and future perspectives. Exploratory Research in Clinical and Social Pharmacy, 20, 100652. [DOI]
Joosse, I. R., Mantel-Teeuwisse, A., van den Ham, H. A., & Cantarero Arevalo, L. (2025). Availability of essential medicines for non-communicable diseases: a scoping review of challenges and opportunities. BMJ Global Health, 10(11). [DOI]
Versteeg, J.-W., Stam, N., Mantel-Teeuwisse, A. K., Timmers, L., Goettsch, W., & Leopold, C. (2025). Coverage With Evidence Development For Medicines with Insufficient Evidence Of Clinical Benefit: Experience From The Netherlands. International Journal of Technology Assessment in Health Care, 41(1), Article e83. [DOI] [Portal]
Callenbach, M. H. E., van den Berg, S., Hulsbosch, A., Hollak, C. E. M., Leopold, C., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2025). Drivers of managed entry agreements to reduce reimbursement challenges of orphan medicinal products: the development of a matrix. Orphanet Journal of Rare Diseases, 20(1), Article 540. [DOI] [Portal]
Lambert, M., van Dijk, L., Benko, R., Llor, C., Lykkegaard, J., Mantel-Teeuwisse, A. K., Pont, L., & Taxis, K. (2025). The role of the community pharmacist in antibiotic use – a commentary on current status and future perspectives. Exploratory Research in Clinical and Social Pharmacy, 20, Article 100652. [DOI] [Portal]
Narsai, K., Leufkens, H. G. M., Brinkhuis, F., Mantel-Teeuwisse, A. K., & van den Ham, H. A. (2025). Transitioning to regulatory harmonisation for medicines: a comparison between Africa and Europe. Drug Discovery Today, 30(8), Article 104416. [DOI]
Hellamand, M., Moleman, T. E., Post, A. P., Mantel-Teeuwisse, A. K., Suleman, F., & Van Den Ham, H. A. (2025). Time to inclusion of selected medicines for priority diseases in National Essential Medicines Lists compared with the WHO Model List. BMJ Global Health, 10(6), Article e018550. [DOI] [Portal]
Samukange, W. T., Kluempers, V., Kafere, C., Heinrich, K., Atemnkeng, J., Khadem Broojerdi, A., Tirane, F., Nkansah, E., Maboko, S., Nhukarume, L., Mutoti, K., Gardasdottir, H., Aineplan, N., Mantel-Teeuwisse, A. K., & Reinhardt, J. (2025). Bridging the gap: enhancing blood regulatory functions in African contexts through comparative analysis. Frontiers in Medicine, 12, Article 1519719. [DOI] [Portal]
Hogervorst, M. A., Vreman, R. A., Oduol, T. A., Mantel-Teeuwisse, A. K., Goettsch, W. G., & Kesselheim, A. S. (2025). Evolving Recommendations for Patient Populations Among Oncology Medicines: A Quantitative and Qualitative Analysis. Clinical Pharmacology and Therapeutics, 118(1), 95-105. [DOI] [Portal]
Saylor, D., Rijke, N., McDonell, J., Laurson-Doube, J., Avasarala, J., Baldin, E., Banerjee, T. K., Bogdanovic, I., Bove, R., Chawla, D. K., Costello, K., Del Giovane, C., Abkari, N. E., Filippini, G., Foschi, M., Gonzalez-Lorenzo, M., Helme, A., Jacobs, D., Kalincik, T., ... Piggott, T. (2025). Recommendations for essential medicines for multiple sclerosis in low-resource settings. Multiple Sclerosis Journal, 31(4), 454-473. [DOI] [Portal]
Callenbach, M. H. E., Vreman, R. A., Leopold, C., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2025). Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability. PharmacoEconomics, 43(1), 53-66. Article 103433. [DOI] [Portal]
2024
Scholarly publications
Callenbach, M., van den Berg, S., Hulsbosch, A., Hollak, C., Leopold, C., Mantel-Teeuwisse, A., & Goettsch, W. (2024). Managed Entry Agreements to Mitigate Uncertainties and Reimbursement Challenges for Orphan Drugs: A Matrix to Determine Their Suitability. Value in Health, 27(12).
Vogler, S., Zimmermann, N., Knoll, V., Salcher-Konrad, M., Windisch, F., Espin, J., Mantel-Teeuwisse, A. K., Panteli, D., Suleman, F., Wirtz, V. J., & Babar, Z. U. D. (2024). ‘We need to be part of the solution’: lessons from the 2024 PPRI Conference on ensuring access to affordable medicines through innovative policies. Journal of Pharmaceutical Policy and Practice, 17(Sup1), Article 2442002. [DOI] [Portal]
Jiu, L., Wang, J., Versteeg, J.-W., Zhang, Y., Liu, L., Somolinos-Simón, F. J., Tapia-Galisteo, J., García-Sáez, G., Hogervorst, M. A., Li, X., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2024). Roadmap to Innovation of HTA Methods (IHTAM): insights from three case studies of quantitative methods. International Journal of Technology Assessment in Health Care, 40(1), 1-10. Article e49. [DOI] [Portal]
Vogler, S., Zimmermann, N., Haasis, M. A., Knoll, V., Espin, J., Mantel-Teeuwisse, A. K., Panteli, D., Suleman, F., Wirtz, V. J., & Babar, Z. U. D. (2024). Innovations in pharmaceutical policies and learnings for sustainable access to affordable medicines. Journal of Pharmaceutical Policy and Practice, 17(S1), Article 2335492. [DOI] [Portal]
Ogar, C. K., Gilbert, H. N., Bloem, L. T., Leopold, C., Bassi, P. U., Katagum, Y. M., Osakwe, A. I., Opadeyi, A. O., Oreagba, I., Mbo, D. N. D., Mantel-Teeuwisse, A. K., & De Bruin, M. L. (2024). Patient-reported outcomes of adverse events after COVID-19 vaccination in Nigeria: A mixed methods study. Vaccine, 42(23), Article 126196. [DOI] [Portal]
Versteeg, J.-W., Vreman, R., Mantel-Teeuwisse, A., & Goettsch, W. (2024). Uncertainty In Long-term Relative Effectiveness Of Medicines In Health Technology Assessment: Comparing Assessments Of Medicines For Spinal Muscular Atrophy, Cystic Fibrosis, And Hypercholesterolemia. Value in Health, 27(10), 1358-1366. [DOI] [Portal]
Callenbach, M. H. E., Schoenmakers, D., Vreman, R. A., Vijgen, S., Timmers, L., Hollak, C. E. M., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2024). Illustrating the financial consequences of outcome-based payment models from a payers perspective- the case of autologous gene therapy atidarsagene autotemcel (Libmeldy®). Value in Health, 27(8), 1046-1057. [DOI] [Portal]
Hogervorst, M. A., van Hattem, C. C., Sonke, G. S., Mantel-Teeuwisse, A. K., Goettsch, W. G., & Bloem, L. T. (2024). Healthcare decision-making for tumour-agnostic therapies in Europe: lessons learned. Drug Discovery Today, 29(7), Article 104031. [DOI] [Repository]
Ooms, G. I., Usman, M. A., Reed, T., van den Ham, H. A., & Mantel-Teeuwisse, A. K. (2024). The impact of scheduling ketamine as an internationally controlled substance on anaesthesia care in Sub-Saharan Africa: a case study and key informant interviews. BMC Health Services Research, 24(1), Article 598. [DOI] [Repository]
Jacobs, T. G., Okemo, D., Ssebagereka, A., Mwehonge, K., Njuguna, E. M., Burger, D. M., Colbers, A., Suleman, F., Mantel-Teeuwisse, A. K., & Ooms, G. I. (2024). Availability and stock-outs of paediatric antiretroviral treatment formulations at health facilities in Kenya and Uganda. HIV Medicine, 25(7), 805-816. [DOI] [Portal]
Narsai, K., Masekela, F. B., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2024). Outer packaging labelling of medicines in Southern African Development Community (SADC) countries: comparative analysis of requirements and transition terms for harmonisation. BMC Health Services Research, 24(1), Article 111. [DOI] [Repository]
Joosse, I. R., Mantel-Teeuwisse, A. K., Suleman, F., & van den Ham, H. A. (2024). Monitoring Access to Child Medicines: Introducing a Standardized Set of Age-Appropriate Medicines. Children, 11(3), Article 266. [DOI] [Repository]
Petro, E., Perumal-Pillay, V., Mantel-Teeuwisse, A. K., van den Ham, H. A., & Suleman, F. (2024). Evaluation of alignment of the reimbursement medicines list for children in Albania with the WHO essential medicines list for children. Journal of Pharmaceutical Policy and Practice, 17(1), 1-18. Article 2290100. [DOI] [Repository]
Joosse, I. R., van den Ham, H. A., Mantel-Teeuwisse, A. K., & Suleman, F. (2024). The caregiver’s experience of childhood cancer treatment in South Africa. Journal of Pharmaceutical Policy and Practice, 17(1), Article 2312382. [DOI] [Repository]
Jiu, L., Wang, J., Javier Somolinos-Simón, F., Tapia-Galisteo, J., García-Sáez, G., Hernando, M., Li, X., Vreman, R. A., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2024). A literature review of quality assessment and applicability to HTA of risk prediction models of coronary heart disease in patients with diabetes. Diabetes Research and Clinical Practice, 209, Article 111574. [DOI] [Repository]
Brinkhuis, F., Goettsch, W. G., Mantel - Teeuwisse, A., & Bloem, L. T. (2024). High cost oncology drugs without proof of added benefit are burdening health systems. The BMJ, 384, Article q511. [DOI] [Repository]
Brinkhuis, F., Goettsch, W. G., Mantel - Teeuwisse, A., & Bloem, L. T. (2024). Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study. The BMJ, 384, Article e077391. [DOI] [Repository]
Jiu, L., Hartog, M., Wang, J., Vreman, R. A., Klungel, O. H., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2024). Tools for assessing quality of studies investigating health interventions using real-world data: a literature review and content analysis. BMJ Open, 14(2), Article e075173. [DOI] [Repository]
Dankers, M., Hek, K., Mantel-Teeuwisse, A. K., van Dijk, L., & Nelissen-Vrancken, M. H. J. M. G. (2024). Adoption of new medicines in primary care: A comparison between the uptake of new oral anticoagulants and diabetes medicines. British Journal of Clinical Pharmacology, 90(3), 819-827. [DOI] [Repository]
Professional publications
Hansen, J., Schackmann, L., van den Ham, R., Leonardo Alves, T., Moriarty, F., Geise, M., Hoebert, J., Mantel - Teeuwisse, A., Wilson, P., Kroneman, M., & van Dijk, L. (2024). Functioning of Directive 89/105/EEC relating to the transparency of measures regulating the prices and reimbursement of medicinal products (‘Transparency Directive’). European Union. https://op.europa.eu/en/publication-detail/-/publication/4f308379-762d-11ef-bbbe-01aa75ed71a1/language-en [Portal]
2023
Scholarly publications
Uzman, N., Selçuk, A., & Mantel-Teeuwisse, A. (2023). Nourishing education to digitally enable pharmacists. In Pharmaceutical Care in Digital Revolution: Blending Digital with Human Innovation, Second Edition (pp. 301-323). Elsevier. [DOI]
Joosse, I. R., Tordrup, D., Glanville, J., Mantel-Teeuwisse, A. K., & van den Ham, H. A. (2023). A systematic review of policies regulating or removing mark-ups in the pharmaceutical supply and distribution chain. Health Policy, 138, 1-9. Article 104919. [DOI] [Repository]
Joosse, I. R., Van Den Ham, H. A., Mantel-Teeuwisse, A. K., & Suleman, F. (2023). Alignment in the registration, selection, procurement and reimbursement of essential medicines for childhood cancers in South Africa. BMJ Global Health, 8(9), Article e012309. [DOI] [Repository]
Dankers, M., Verlegh, P., Weber, K., Nelissen-Vrancken, M., van Dijk, L., & Mantel-Teeuwisse, A. (2023). Marketing of medicines in primary care: An analysis of direct marketing mailings and advertisements. PLoS One, 18(8 August), Article e0290603. [DOI] [Repository]
Ooms, G. I., van Oirschot, J., de Kant, D., van den Ham, H. A., Mantel-Teeuwisse, A. K., & Reed, T. (2023). Barriers to accessing internationally controlled essential medicines in sub-saharan Africa: A scoping review. International Journal of Drug Policy, 118, Article 104078. [DOI] [Repository]
Postma, D. J., Notenboom, K., De Smet, P. A. G. M., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2023). Medicine shortages: impact behind numbers. Journal of Pharmaceutical Policy and Practice, 16(1), 1-12. Article 44. [DOI] [Repository]
Etukakpan, A., Uzman, N., Ozer, O., Tofade, T., Leite, S. N., Joda, A., Choonara, Y., Mwila, C., Azzopardi, L. M., Mantel-Teeuwisse, A. K., Rahal, M., Darwish, R., Lee, B. J., Shakya, R., Gallagher, P. J., Moreau, P., Lourenço, L., McKinnon, R. A., & Altiere, R. J. (2023). Transforming pharmaceutical education: A needs-based global analysis for policy development. Exploratory Research in Clinical and Social Pharmacy, 9, Article 100234. [DOI] [Repository]
Ogar, C. K., Quick, J., Gilbert, H. N., Vreman, R. A., Mantel-Teeuwisse, A. K., & Mugunga, J. C. (2023). Adverse Events to SARS-CoV-2 (COVID-19) Vaccines and Policy Considerations that Inform the Funding of Safety Surveillance in Low- and Middle-Income Countries: A Mixed Methods Study. Drug Safety, 46(4), 357-370. [DOI] [Repository]
Callenbach, M. H. E., Vreman, R. A., Schoenmakers, D., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2023). The Desirability of Implementing an Outcomebased Delayed Payment Model for Autologous Gene Therapy Atidarsagene Autotemcel (libmeldy$142#(r)$144#). Value in Health, 26(6), S212-S213.
Hogervorst, M., Vreman, R. A., Mantel-Teeuwisse, A. K., Goettsch, W. G., & Kesselheim, A. S. (2023). Evolving Pico Characteristics in the Early Oncology Treatment Lifecycle: Differences From Trials to Treatment Guidelines. Value in Health, 26(6), S218-S219. [DOI]
Hogervorst, M. A., Møllebæk, M., Vreman, R. A., Lu, T. A., Wang, J., De Bruin, M. L., Leufkens, H. G. M., Mantel-Teeuwisse, A., & Goettsch, W. (2023). Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts. BMJ Open, 13(8), Article e072309. [DOI] [Repository]
Joosse, I. R., Mantel-Teeuwisse, A. K., Suleman, F., & van den Ham, H. A. (2023). Sustainable Development Goal indicator for measuring availability and affordability of medicines for children: a proof-of-concept study. BMJ Open, 13(4), Article e065929. [DOI] [Repository]
Kusynová, Z., van den Ham, H. A., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2023). Pharmaceutical Scientists' Perspectives on Capacity Building in Pharmaceutical Sciences. Journal of Pharmaceutical Sciences, 112(7), 1997-2003. [DOI] [Repository]
Kusynová, Z., Bais, Y., van den Ham, H. A., Mantel-Teeuwisse, A. K., Etame-Loe, G., Kaale, E., Sarr, S. O., Guiet-Mati, F., & Bourdillon-Esteve, P. (2023). Improved knowledge on substandard and falsified (SF) medical products through a dedicated course for pharmacy students at three universities in sub-Saharan Africa. BMJ Global Health, 6(3 S), Article e009367. [DOI] [Repository]
Joosse, I. R., Wirtz, V. J., van Mourik, A. T., Wagner, B. A., Mantel-Teeuwisse, A. K., Suleman, F., & van den Ham, H. A. (2023). SDG indicator 3.b.3 - an analysis of its robustness and challenges for measuring access to medicines for children. BMC Health Services Research, 23(1), Article 574. [DOI] [Repository]
Samukange, W. T., Lu, T.-A., Souverein, P. C., Gardarsdottir, H., & Mantel-Teeuwisse, A. K. (2023). Suspected adverse reactions reported for blood, blood components, and blood products in VigiBase. Transfusion, 63(5), 982-992. [DOI] [Repository]
Hogervorst, M. A., Vreman, R. A., Zawada, A., Zielińska, M., Dawoud, D. M., de Jong, B. A., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2023). Synergy between health technology assessments and clinical guidelines for multiple sclerosis. Clinical and Translational Science, 16(5), 835-849. [DOI] [Repository]
Atikeler, E. K., Fasseeh, A. N., Mantel-Teeuwisse, A. K., Caliskan, Z., Oner, Z. G., Kizilay, H., Kalo, Z., & Goettsch, W. (2023). Health technology assessment in Türkiye: Current status and perspectives on future implementation. Health Policy and Technology, 12(1), Article 100701. [DOI] [Repository]
Joosse, I. R., Tordrup, D., Glanville, J., Kotas, E., Mantel-Teeuwisse, A. K., & van den Ham, H. A. (2023). Evidence on the effectiveness of policies promoting price transparency -: A systematic review. Health Policy, 134, Article 104681. [DOI] [Repository]
Joosse, I. R., Tordrup, D., Bero, L., Mantel-Teeuwisse, A. K., & van den Ham, H. A. (2023). A critical review of methodologies used in pharmaceutical pricing policy analyses. Health Policy, 134, Article 104576. [DOI] [Repository]
Professional publications
Dankers, M., Verlegh, P. W. J., Weber, K., Nelissen-Vrancken, H. J. M. G. M., van Dijk, L., & Mantel-Teeuwisse, A. K. (2023). Wat kunt u doen om … niet beïnvloed te worden? Nederlands Tijdschrift voor Geneeskunde, 168, Article D7997.
Akpinar, L., Amiri, A., van den Broek, M., van Kampen, T., Kurt, N., Sabriye, I., Singh, A., van Sommeren, I., Mantel - Teeuwisse, A., & Rijcken, C. (2023). Hybride zorg komt eraan: face-to-face-zorg in combinatie met digitale innovaties: Digitalisering faciliteert monitoring therapietrouw en patientveiligheid. Pharmaceutisch Weekblad, (25). https://www.pw.nl/achtergrond/2023/hybride-zorg-komt-eraan-face-to-face-zorg-in-combinatie-met-digitale-innovaties
Dankers, M., Verlegh, P., Weber, K., Nelissen-Vrancken, M. H. J. M. G., van Dijk, L., & Mantel - Teeuwisse, A. (2023). Wat kunt u doen om ... niet beinvloed te worden? Nederlands Tijdschrift voor Geneeskunde, 167, Article D79997. https://www.ntvg.nl/artikelen/wat-kunt-u-doen-om-niet-beinvloed-te-worden
European Commission, Directorate-General for Health and Food Safety, Mantel - Teeuwisse, A., Bloem, L. T., Boon, W., De Bruin, M. L., Hoekman, J., Klein, K., Stolk, P., & Vreman, R. (2023). Study in support of the evaluation and impact assessment of the EU general pharmaceuticals legislation: Analytical Report. Publications Office of the European Union. [DOI] [Repository]
European Commission, Directorate-General for Health and Food Safety, Mantel - Teeuwisse, A., Bloem, L. T., Boon, W., De Bruin, M. L., Hoekman, J., Klein, K., Stolk, P., & Vreman, R. (2023). Study in support of the evaluation and impact assessment of the EU general pharmaceuticals legislation: Evaluation Report. Publications Office of the European Union. [DOI] [Repository]
2022
Scholarly publications
Jiu, L., Wang, J., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2022). To Merge Randomized Controlled Trials and Real-world Evidence with Bayesian Network Meta-regression: A Case Study in Patients with Myelodysplastic Syndromes. Value in Health, 25(12), S354-S354.
Jiu, L., Junfeng, W., Vreman, R. A., Mantel-Teeuwisse, A. K., & Goettsch, W. (2022). The Methodological Quality of Retrospective Observational Studies to Evaluate Glucose Monitoring Systems in Diabetes Patients: A Systematic Review. Value in Health, 25(1), S209-S209.
Hogervorst, M., Mollebaek, M., Vreman, R. A., Wang, J., Mantel-Teeuwisse, A. K., & Goettsch, W. (2022). Building Bridges Between Regulation, Health Technology Assessment and Clinical Guideline Development. Value in Health, 25(12), S233-S234.
Jiu, L., Hartog, M. K., Wang, J., Vreman, R. A., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2022). Applicability of Appraisal Tools of Real-World Evidence in Health Technology Assessment: A Literature Review and Content Analysis. Value in Health, 25(12), S389-S389.
Versteeg, J. W., Hogervorst, M., Mantel-Teeuwisse, A. K., Goettsch, W. G., & Vreman, R. A. (2022). Uncertainty Regarding the Long-term Effectiveness of New Therapies in Health Technology Assessment. Value in Health, 25(12), S305-S305.
Callenbach, M. H. E., Vreman, R. A., Goettsch, W. G., & Mantel-Teeuwisse, A. K. (2022). Payment and Reimbursement Models for Innovative High-priced Hospital Drugs in the Netherlands: A Survey of Stakeholder's Attitudes and Experiences. Value in Health, 25(12), S261-S261.
Callenbach, M. H. E., Vreman, R. A., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2022). When Reality Does Not Meet Expectations-Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs. International Journal of Environmental Research and Public Health, 20(1), Article 340. [DOI] [Repository]
Joosse, I. R., Mantel-Teeuwisse, A. K., Wirtz, V. J., Suleman, F., & van den Ham, H. A. (2022). Missing data on accessibility of children's medicines. Bulletin of the World Health Organization, 100(10), 636-642. [DOI] [Repository]
Ismail, M., Mantel - Teeuwisse, A., & Mirza, Z. (2022). The Pharmaceutical System and Its Component: Regulation and Management and Associated Challenges. In S. Siddiqi, A. Mataria, K. Rouleau, & M. Iqbal (Eds.), Making Health Systems Work in Low and Middle Income Countries: Textbook for Public Health Practitioners (pp. 102-117). Cambridge University Press. [DOI] [Repository]
Dankers, M., van den Berk-Bulsink, M. J. E., van Dalfsen-Slingerland, M., Nelissen-Vrancken, H. J. M. G., Mantel-Teeuwisse, A. K., & van Dijk, L. (2022). Non-adherence to guideline recommendations for insulins: a qualitative study amongst primary care practitioners. BMC Primary Care, 23(1), Article 150. [DOI] [Repository]
Ooms, G. I., van Oirschot, J., Okemo, D., Reed, T., van den Ham, H. A., & Mantel-Teeuwisse, A. K. (2022). Healthcare workers’ perspectives on access to sexual and reproductive health services in the public, private and private not-for-profit sectors: insights from Kenya, Tanzania, Uganda and Zambia. BMC Health Services Research, 22(1), 1-11. Article 873. [DOI] [Repository]
Postma, D. J., De Smet, P. A. G. M., Notenboom, K., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2022). Impact of medicine shortages on patients - a framework and application in the Netherlands. BMC Health Services Research, 22(1), 1-12. Article 1366. [DOI] [Repository]
Kusynová, Z., van den Ham, H. A., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2022). Longitudinal study of Good Pharmacy Practice roles covered at the annual world pharmacy congresses 2003–2019. Journal of Pharmaceutical Policy and Practice, 15(1), 1-14. Article 94. [DOI] [Repository]
Dankers, M., Hek, K., Nelissen-Vrancken, M., Houweling, S. T., Mantel-Teeuwisse, A., & van Dijk, L. (2022). Newer long-acting insulin prescriptions for patients with type 2 diabetes: prevalence and practice variation in a retrospective cohort study. British Journal of General Practice, 72(719), E430-E436. [DOI] [Repository]
Leufkens, H. G., Kusynová, Z., Aitken, M., Hoekman, J., Stolk, P., Klein, K., & Mantel-Teeuwisse, A. K. (2022). Four scenarios for the future of medicines and social policy in 2030. Drug Discovery Today, 27(8), 2252-2260. [DOI] [Repository]
Komen, J. J., Pottegård, A., Mantel-Teeuwisse, A. K., Forslund, T., Hjemdahl, P., Wettermark, B., Hallas, J., Olesen, M., Bennie, M., Mueller, T., Carragher, R., Karlstad, Ø., Kjerpeseth, L. J., & Klungel, O. H. (2022). Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study. European Heart Journal, 43(37), 3528-3538. [DOI] [Repository]
Hogervorst, M. A., Pontén, J., Vreman, R. A., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2022). Real World Data in Health Technology Assessment of Complex Health Technologies. Frontiers in Pharmacology, 13, 1-9. Article 837302. [DOI] [Repository]
Perehudoff, K., Kibira, D., Wuyts, E., Pericas, C., Omwoha, J., van den Ham, H. A., Mantel-Teeuwisse, A. K., & Michielsen, K. (2022). A comparative human rights analysis of laws and policies for adolescent contraception in Uganda and Kenya. Reproductive Health, 19(1), 1-14. Article 37. [DOI] [Repository]
Jiu, L., Hogervorst, M. A., Vreman, R. A., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2022). Understanding innovation of health technology assessment methods: the IHTAM framework. International Journal of Technology Assessment in Health Care, 38(1), 1-10. Article e16. [DOI] [Repository]
Vreman, R. A., Strigkos, G., Leufkens, H. G. M., Schünemann, H. J., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2022). Addressing uncertainty in relative effectiveness assessments by HTA organizations. International Journal of Technology Assessment in Health Care, 38(1), 1-8. Article e17. [DOI] [Repository]
Hogervorst, M. A., Vreman, R. A., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2022). Reported Challenges in Health Technology Assessment of Complex Health Technologies. Value in Health, 25(6), 992-1001. [DOI] [Repository]
Bloem, L. T., Bot, R. E., Mantel-Teeuwisse, A. K., van der Elst, M. E., Sonke, G. S., Klungel, O. H., Leufkens, H. G. M., & Hoekman, J. (2022). Pre-approval and post-approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: a comparison with standard approved cancer drugs. British Journal of Clinical Pharmacology, 88(5), 2169-2179. [DOI] [Repository]
Kusynová, Z., Pauletti, G. M., van den Ham, H. A., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2022). Unmet medical need as a driver for pharmaceutical sciences - a survey among scientists. Journal of Pharmaceutical Sciences, 111, 1318-1324. [DOI] [Repository]
Komen, J., Pottegård, A., Hjemdahl, P., Mantel-Teeuwisse, A. K., Wettermark, B., Hellfritzsch, M., Hallas, J., Herings, R., Smits, L., Forslund, T., & Klungel, O. (2022). Non-vitamin K antagonist oral anticoagulants, proton pump inhibitors and gastrointestinal bleeds. Heart, 108, 613-618. Article 319332. [DOI] [Repository]
Vreman, R. A., Bloem, L. T., van Oirschot, S., Hoekman, J., van der Elst, M. E., Leufkens, H. G., Klungel, O. H., Goettsch, W. G., & Mantel-Teeuwisse, A. K. (2022). The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs. International Journal of Health Policy and Management, 11(5), 642-650. [DOI] [Repository]
Professional publications
Bouzeryouh, S., Kadrić, Z., Smorenburg, K., Mantel-Teeuwisse, A., & Rijcken, C. (2022). Op weg naar makkelijker uitwisseling van medische data: Cursisten Digitale Zorg anticiperen met projectvoorstellen op de toekomst. Pharmaceutisch Weekblad, 57(37), 14-16. https://www.pw.nl/achtergrond/2022/op-weg-naar-makkelijker-uitwisseling-van-medische-data
Other output
Hogervorst, M., Goettsch, W., Mantel-Teeuwisse, A. K., Bloem, L., & Vreman, R. A. (2022). Uncertainties Around Tumour Agnostic Therapies in Europe: Barriers and Facilitators of Patient Access. Value in Health, 25(12), S266-S266.
2021
Scholarly publications
Kusynová, Z., Kicken, M., van den Ham, H. A., & Mantel-Teeuwisse, A. K. (2021). Identifying the teaching content on substandard and falsified medical products in global pharmacy education as critical public health issue. Pharmacy Education, 21, 504-516. [DOI] [Repository]
Ooms, G. I., van Oirschot, J., Waldmann, B., Okemo, D., Mantel-Teeuwisse, A. K., van den Ham, H. A., & Reed, T. (2021). The burden of snakebite in rural communities in Kenya: A household survey. American Journal of Tropical Medicine and Hygiene, 105(3), 828-836. [DOI] [Repository]
Komen, J. J., Pottegård, A., Mantel-Teeuwisse, A. K., Forslund, T., Hjemdahl, P., Wettermark, B., Hellfritzsch, M., Hallas, J., Olesen, M., Bennie, M., Mueller, T., Voss, A., Schink, T., Haug, U., Kollhorst, B., Karlstad, Ø., Kjerpeseth, L. J., & Klungel, O. H. (2021). Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries. Europace, 23(11), 1722-1730. [DOI] [Repository]
Samukange, W. T., Kluempers, V., Porwal, M., Mudyiwenyama, L., Mutoti, K., Aineplan, N., Gardarsdottir, H., Mantel-Teeuwisse, A. K., & Nuebling, C. M. (2021). Implementation and performance of haemovigilance systems in 10 sub-saharan African countries is sub-optimal. BMC Health Services Research, 21(1), 1-12. Article 1258. [DOI] [Repository]
Narsai, K., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2021). Linking market authorizations of medicines with disease burden in South Africa. Journal of Pharmaceutical Policy and Practice, 14(1), 1-10. Article 33. [DOI] [Repository]
Dankers, M., Nelissen-Vrancken, M. H. J. M. G., Hart, B. H., Lambooij, A. C., van Dijk, L., & Mantel-Teeuwisse, A. K. (2021). Alignment between outcomes and minimal clinically important differences in the Dutch type 2 diabetes mellitus guideline and healthcare professionals’ preferences. Pharmacology Research and Perspectives, 9(3), 1-12. Article e00750. [DOI] [Repository]
Kibira, D., Asiimwe, C., Muwonge, M., van den Ham, H. A., Reed, T., Leufkens, H. G., & Mantel-Teeuwisse, A. K. (2021). Donor Commitments and Disbursements for Sexual and Reproductive Health Aid in Kenya, Tanzania, Uganda and Zambia. Frontiers in Public Health, 9, 1-12. Article 645499. [DOI] [Repository]
Komen, J. J., Forslund, T., Mantel-Teeuwisse, A. K., Klungel, O. H., Von Euler, M., Braunschweig, F., Wallén, H., & Hjemdahl, P. (2021). Response to: Kumar N, Ahmed M. Letter to the editor in response to Komen et al. 2021. European Heart Journal - Cardiovascular Pharmacotherapy, 7(3), E31. [DOI] [Repository]
Mantel-Teeuwisse, A. K., Meilianti, S., Khatri, B., Yi, W., Azzopardi, L. M., Gómez, J. A., Gülpınar, G., Bennara, K., & Uzman, N. (2021). Digital health in pharmacy education: Preparedness and responsiveness of pharmacy programmes. Education Sciences, 11(6), 1-13. Article 296. [DOI] [Repository]
Ooms, G. I., van Oirschot, J., Okemo, D., Waldmann, B., Erulu, E., Mantel-Teeuwisse, A. K., van den Ham, H. A., & Reed, T. (2021). Availability, affordability and stock-outs of commodities for the treatment of snakebite in kenya. PLoS Neglected Tropical Diseases, 15(8), 1-20. Article e0009702. [DOI] [Repository]
Vreman, R. A., Geenen, J. W., Knies, S., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., & Goettsch, W. G. (2021). Comment on "Deterministic Sensitivity Analysis Under Ignorance". PharmacoEconomics, 39(10), 1199. [DOI] [Repository]
Bloem, L. T., Karomi, M., Hoekman, J., van der Elst, M. E., Leufkens, H. G. M., Klungel, O. H., & Mantel-Teeuwisse, A. K. (2021). Comprehensive evaluation of post-approval regulatory actions during the drug lifecycle–a focus on benefits and risks. Expert Opinion on Drug Safety, 20(11), 1433-1442. [DOI] [Repository]
Broekhoff, T. F., Sweegers, C. C. G., Krijkamp, E. M., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., Goettsch, W. G., & Vreman, R. A. (2021). Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios. Value in Health, 24(6), 759-769. [DOI] [Repository]
Bloem, L. T., Vreman, R. A., Peeters, N. W. L., Hoekman, J., van der Elst, M. E., Leufkens, H. G. M., Klungel, O. H., Goettsch, W. G., & Mantel-Teeuwisse, A. K. (2021). Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies. Clinical and Translational Science, 14(4), 1566-1577. [DOI] [Repository]
Kibira, D., Ooms, G. I., Van Den Ham, H. A., Namugambe, J. S., Reed, T., Leufkens, H. G. M., & Mantel-Teeuwisse, A. (2021). Access to oxytocin and misoprostol for management of postpartum haemorrhage in Kenya, Uganda and Zambia: A cross-sectional assessment of availability, prices and affordability. BMJ Open, 11(1), 1-8. Article e042948. [DOI] [Repository]
Vogler, S., Zimmermann, N., Babar, Z. U. D., Busse, R., Espin, J., Mantel-Teeuwisse, A. K., Panteli, D., Suleman, F., & Wirtz, V. J. (2021). Addressing the medicines access challenge through balance, evidence, collaboration and transparency: key take-away lessons of the 4th PPRI Conference. Journal of Pharmaceutical Policy and Practice, 14(1), 1-5. Article 18. [DOI] [Repository]
Kibira, D., Ssebagereka, A., van den Ham, H. A., Opigo, J., Katamba, H., Seru, M., Reed, T., Leufkens, H. G., & Mantel-Teeuwisse, A. K. (2021). Trends in access to anti‐malarial treatment in the formal private sector in Uganda: an assessment of availability and affordability of first‐line anti‐malarials and diagnostics between 2007 and 2018. Malaria Journal, 20(1), 1-8. Article 142. [DOI] [Repository]
Ooms, G. I., van Oirschot, J., Waldmann, B., von Bernus, S., van den Ham, H. A., Mantel-Teeuwisse, A. K., & Reed, T. (2021). The Current State of Snakebite Care in Kenya, Uganda, and Zambia: Healthcare Workers' Perspectives and Knowledge, and Health Facilities' Treatment Capacity. American Journal of Tropical Medicine and Hygiene, 104(2), 774–782. [DOI] [Repository]
Komen, J. J., Forslund, T., Mantel-Teeuwisse, A. K., Klungel, O. H., von Euler, M., Braunschweig, F., Wallén, H., & Hjemdahl, P. (2021). Association of preceding antithrombotic therapy in atrial fibrillation patients with ischaemic stroke, intracranial haemorrhage, or gastrointestinal bleed and mortality. European heart journal. Cardiovascular pharmacotherapy, 7(1), 3–10. [DOI] [Repository]
Professional publications
Smits, B., Pikkaart, F., Rieter, Q., Van Dam, V., Rijcken, C., & Mantel-Teeuwisse, A. (2021). Hoe COVID-19 voor een versnelling van digitalisering in de apotheek zorgt: Veel innovaties bieden oplossingen voor al langer bestaande problemen. Pharmaceutisch Weekblad, 156(39), 14-16. https://www.pw.nl/achtergrond/2021/hoe-covid-19-voor-een-versnelling-van-digitalisering-in-de-apotheek-zorgt [Repository]
2020
Scholarly publications
Tordrup, D., van den Ham, R., Leopold, C., Glanville, J., Kotas, E., & Mantel - Teeuwisse, A. (2020). Web Annex A: Systematic reviews for the update of the WHO Guideline on country pharmaceutical pricing policies. In WHO guideline on country pharmaceutical pricing policies World Health Organization. http://ncbi.nlm.nih.gov/books/NBK570141/
Komen, J. J., Heerdink, E. R., Klungel, O. H., Mantel-Teeuwisse, A. K., Forslund, T., Wettermark, B., & Hjemdahl, P. (2020). Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk. European heart journal. Cardiovascular pharmacotherapy, 7(FI1), f72-f80. [DOI] [Repository]
Vranken, M. J. M., Linge-Dahl, L., Mantel-Teeuwisse, A. K., Radbruch, L., Schutjens, M. H. DB., Scholten, W., Payne, S., & Jünger, S. (2020). The perception of barriers concerning opioid medicines: A survey examining differences between policy makers, healthcare professionals and other stakeholders. Palliative Medicine, 34(4), 493-503. [DOI] [Repository]
Koster, A. S., Mantel-Teeuwisse, A. K., Woerdenbag, H. J., Mulder, W. M. C., Wilffert, B., Schalekamp, T., Buurma, H., Wilting, I., & Westein, M. P. D. (2020). Alignment of CanMEDS-based Undergraduate and Postgraduate Pharmacy Curricula in The Netherlands. Pharmacy, 8(3), Article 117. [DOI] [Repository]
Vreman, R. A., Mantel-Teeuwisse, A. K., Hövels, A. M., Leufkens, H. G. M., & Goettsch, W. G. (2020). Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations. Value in Health, 23(1), 10-16. [DOI] [Repository]
Vreman, R. A., Naci, H., Goettsch, W. G., Mantel-Teeuwisse, A. K., Schneeweiss, S. G., Leufkens, H. G. M., & Kesselheim, A. S. (2020). Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe. Clinical Pharmacology and Therapeutics, 108(2), 350-357. [DOI] [Repository]
Vreman, R. A., de Ruijter, A. S., Zawada, A., Tafuri, G., Stoyanova-Beninska, V., O'Connor, D., Naumann-Winter, F., Wolter, F., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., Sidiropoulos, I., Larsson, K., & Goettsch, W. G. (2020). Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizations. Drug Discovery Today, 25(7), 1223-1231. [DOI] [Repository]
Vreman, R. A., Belitser, S. V., Mota, A. T. M., Hövels, A. M., Goettsch, W. G., Roes, K. C. B., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2020). Efficacy gap between phase II and subsequent phase III studies in oncology. British Journal of Clinical Pharmacology, 86(7), 1306-1313. [DOI] [Repository]
Ooms, G. I., Kibira, D., Reed, T., Van Den Ham, H. A., Mantel-Teeuwisse, A. K., & Buckland-Merrett, G. (2020). Access to sexual and reproductive health commodities in East and Southern Africa: A cross-country comparison of availability, affordability and stock-outs in Kenya, Tanzania, Uganda and Zambia. BMC Public Health, 20(1), Article 1053. [DOI] [Repository]
Tordrup, D., Van Den Ham, H. A., Glanville, J., & Mantel-Teeuwisse, A. K. (2020). Systematic reviews of ten pharmaceutical pricing policies - A research protocol. Journal of Pharmaceutical Policy and Practice, 13(1), Article 22. [DOI] [Repository]
Moerlie, A. R., VAN UDEN, R. C., Mantel-Teeuwisse, A. K., VAN DEN BEMT, P., & Becker, M. L. (2020). Inpatient prescribing of dual antiplatelet therapy according to the guidelines: A prospective intervention study. Pharmacy Practice, 18(2), Article 1803. [DOI] [Repository]
Vreman, R. A., Broekhoff, T. F., Leufkens, H. G. M., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2020). Application of managed entry agreements for innovative therapies in different settings and combinations: A feasibility analysis. International Journal of Environmental Research and Public Health, 17(22), Article 8309. [DOI] [Repository]
Lilih, S., Kooij, M., Mantel-Teeuwisse, A., & Mhammad, B. A. S. (2020). Medicijnverspilling in apotheken fors onderschat. Pharmaceutisch Weekblad, 155(27-28), 22-23. https://www.pw.nl/achtergrond/2020/medicijnverspilling-in-apotheken-fors-onderschat
Vreman, R. A., Geenen, J. W., Knies, S., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., & Goettsch, W. G. (2020). The Application and Implications of Novel Deterministic Sensitivity Analysis Methods. PharmacoEconomics, 39(1), 1-17. [DOI] [Repository]
Althunian, T. A., de Boer, A., Mantel-Teeuwisse, A. K., Groenwold, R. H. H., Gispen-de Wied, C. C., Leufkens, H. G. M., & Klungel, O. H. (2020). Assessment of the Regulatory Dialogue Between Pharmaceutical Companies and the European Medicines Agency on the Choice of Noninferiority Margins. Clinical Therapeutics, 42(8), 1588-1594. [DOI] [Repository]
Samukange, W. T., Gardarsdottir, H., Leufkens, H. G. M., & Mantel-Teeuwise, A. K. (2020). Selection of Blood, Blood Components, and Blood Products as Essential Medicines in 105 Low- and Middle-Income Countries. Transfusion Medicine Reviews, 34(2), 94-100. [DOI] [Repository]
Komen, J. J., Hjemdahl, P., Mantel-Teeuwisse, A. K., Klungel, O. H., Wettermark, B., & Forslund, T. (2020). Concomitant Anticoagulant and Antidepressant Therapy in Atrial Fibrillation Patients and Risk of Stroke and Bleeding. Clinical Pharmacology and Therapeutics, 107(1), 287-294. [DOI] [Repository]
2019
Scholarly publications
Vreman, R. A., Bouvy, J. C., Bloem, L. T., Hövels, A. M., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., & Goettsch, W. G. (2019). Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs. Clinical Pharmacology and Therapeutics, 105(3), 684-691. [DOI] [Repository]
Vranken, M. J. M., Schutjens, M. H. D. B., & Mantel-Teeuwisse, A. K. (2019). The double opioid crisis: A call for balance. Pharmacoepidemiology and Drug Safety, 28(1), 1-3. [DOI] [Repository]
Vargas-Pelaez, C. M., Rover, M. R. M., Soares, L., Blatt, C. R., Mantel-Teeuwisse, A. K., Rossi, F. A., Restrepo, L. G., Latorre, M. C., López, J. J., Bürgin, M. T., Silva, C., Leite, S. N., & Farias, M. R. (2019). Judicialization of access to medicines in four Latin American countries: a comparative qualitative analysis. International Journal for Equity in Health, 18(1), Article 68. [DOI] [Repository]
Nartey, E. T., Tetteh, R. A., Yankey, B. A., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., Dodoo, A. N. O., & Lartey, M. (2019). Tenofovir-associated renal toxicity in a cohort of HIV infected patients in Ghana. BMC Research Notes, 12(1), Article 445. [DOI] [Repository]
Jacobs, T. G., Robertson, J., van den Ham, H. A., Iwamoto, K., Bak Pedersen, H., & Mantel-Teeuwisse, A. K. (2019). Assessing the impact of law enforcement to reduce over-the-counter (OTC) sales of antibiotics in low- and middle-income countries; a systematic literature review. BMC Health Services Research, 19(1), Article 536. [DOI] [Repository]
Bloem, L. T., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., De Bruin, M. L., Klungel, O. H., & Hoekman, J. (2019). Postauthorization Changes to Specific Obligations of Conditionally Authorized Medicines in the European Union: A Retrospective Cohort Study. Clinical Pharmacology and Therapeutics, 105(2), 426-435. [DOI] [Repository]
Minnema, L. A., Giezen, T. J., Gardarsdottir, H., Egberts, T. C. G., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2019). Post-marketing dosing changes in the label of biologicals. British Journal of Clinical Pharmacology, 85(4), 715-721. [DOI] [Repository]
2018
Scholarly publications
Postma, D. J., De Smet, P. A. G. M., Gispen-de Wied, C. C., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2018). Drug Shortages From the Perspectives of Authorities and Pharmacy Practice in the Netherlands: An Observational Study. Frontiers in Pharmacology, 9, Article 1243. [DOI] [Repository]
Leonardo Alves, T., Poplavska, E., Mezinska, S., Salmane-Kulikovska, I., Andersone, L., Mantel-Teeuwisse, A. K., & Mintzes, B. (2018). Disease awareness campaigns in printed and online media in Latvia: Cross-sectional study on consistency with WHO ethical criteria for medicinal drug promotion and European standards 11 Medical and Health Sciences 1117 Public Health and Health Services. BMC Public Health, 18, Article 1322. [DOI] [Repository]
Bindraban, A. N., Rolvink, J., Berger, F. A., van den Bemt, P. M. L. A., Kuijper, A. F. M., van der Hoeven, R. T. M., Mantel-Teeuwisse, A. K., & Becker, M. L. (2018). Development of a risk model for predicting QTc interval prolongation in patients using QTc-prolonging drugs. International Journal of Clinical Pharmacy, 40(5), 1372-1379. [DOI] [Repository]
Ivanovska, V., Angelovska, B., Van Dijk, L., Zdravkovska, M., Leufkens, H. G., & Mantel-Teeuwisse, A. K. (2018). Change in parental knowledge, attitudes and practice of antibiotic use after a national intervention programme. European Journal of Public Health, 28(4), 724-729. [DOI] [Repository]
Insani, W. N., Pacurariu, A. C., Mantel-Teeuwisse, A. K., & Gross-Martirosyan, L. (2018). Characteristics of drugs safety signals that predict safety related product information update. Pharmacoepidemiology and Drug Safety, 27(7), 789-796. [DOI] [Repository]
Forslund, T., Komen, J. J., Andersen, M., Wettermark, B., von Euler, M., Mantel-Teeuwisse, A. K., Braunschweig, F., & Hjemdahl, P. (2018). Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants. Stroke, 49(9), 2122-2128. [DOI] [Repository]
Jacobs, T. G., Hilda Ampadu, H., Hoekman, J., Dodoo, A. N. O., & Mantel-Teeuwisse, A. K. (2018). The contribution of Ghanaian patients to the reporting of adverse drug reactions: a quantitative and qualitative study. BMC Public Health, 18(1), Article 1384. [DOI] [Repository]
Althunian, T., De Boer, A., Mantel-Teeuwisse, A. K., Groenwold, R. H. H., Gispen-De Wied, C. C., Leufkens, H. G. M., Elferink, A., & Klungel, O. H. (2018). Regulatory challenges in the design of non-inferiority trials: Evaluating scientific advice letters from the European Medicines Agency (EMA). Pharmacoepidemiology and Drug Safety, 27(S2), 149. [DOI] [Repository]
Taghipour Bazargani, Y., Ugurlu, M., de Boer, A., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2018). Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries. BMC Cardiovascular Disorders, 18(1), Article 126. [DOI] [Repository]
van den Heuvel, J. M., Hövels, A. M., Büller, H. R., Mantel-Teeuwisse, A. K., de Boer, A., & Maitland-van der Zee, A. H. (2018). NOACs replace VKA as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in The Netherlands. Thrombosis Journal, 16(7). [DOI] [Repository]
Vranken, M. J. M., Mantel-Teeuwisse, A. K., Schutjens, M.-H. D. B., Scholten, W. K., Jünger, S., Medic, D. R., & Leufkens, H. G. M. (2018). Access to Strong Opioid Analgesics in the Context of Legal and Regulatory Barriers in Eleven Central and Eastern European Countries. Journal of Palliative Medicine, 21(7), 963-969. [DOI] [Repository]
Lepelaars, L. R. A., Renda, F., Pani, L., Pimpinella, G., Leufkens, H. G. M., Trifirò, G., Tafuri, G., Mantel-Teeuwisse, A. K., & Trotta, F. (2018). Comparing safety information of biosimilars with their originators: A cross-sectional analysis of European risk management plans. British Journal of Clinical Pharmacology, 84(4), 738-763. [DOI] [Repository]
Ankrah, D. N. A., Darko, D. M., Sabblah, G., Mantel-Teeuwisse, A., & Leufkens, B. (2018). Reporting of adverse events following immunizations in Ghana–Using disproportionality analysis reporting ratios. Human Vaccines and Immunotherapeutics, 14(1), 172-178. [DOI] [Repository]
Heemskerk, C. P. M., Pereboom, M., van Stralen, K., Berger, F. A., van den Bemt, P. M. L. A., Kuijper, A. F. M., van der Hoeven, R. T. M., Mantel-Teeuwisse, A. K., & Becker, M. L. (2018). Risk factors for QTc interval prolongation. European Journal of Clinical Pharmacology, 74(2), 183-191. [DOI] [Repository]
Ivanovska, V., Hek, K., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., & van Dijk, L. (2018). Age-Specific Antibiotic Prescribing and Adherence to Guidelines in Pediatric Patients in Primary Care. Pediatric Infectious Disease Journal, 37(3), 218-223. [DOI] [Repository]
Fazeli Farsani, S., Abdullah-Koolmees, H., Souverein, P. C., de Boer, A., & Mantel-Teeuwisse, A. K. (2018). Psychiatric medication use before and after the onset of type 1 diabetes in children and adolescents: A population-based cohort study. Pediatric Diabetes, 19(1), 121-128. [DOI] [Repository]
2017
Scholarly publications
Heemskerk, C. P. M., Woldman, E., Pereboom, M., van der Hoeven, R. T. M., Mantel-Teeuwisse, A., Van Gemeren, C., & Becker, M. L. (2017). Ciprofloxacin does not Prolong the QTc Interval: A Clinical Study in ICU Patients and Review of the Literature. Journal of Pharmacy and Pharmaceutical Sciences, 20(1), 360-364. [DOI] [Repository]
Meneses Leonardo Alves, T., Mantel-Teeuwisse, A. K., Paschke, A., Leufkens, H. G. M., Puil, L., Poplavska, E., & Mintzes, B. (2017). Unbranded advertising of prescription medicines to the public by pharmaceutical companies. Cochrane Database of Systematic Reviews, 2017(7), Article CD012699. [DOI] [Repository]
Hoebert, J. M., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., & Van Dijk, L. (2017). Variability in market uptake of psychotropic medications in Europe reflects cultural diversity. BMC Health Services Research, 17(1), Article 702. [DOI] [Repository]
Kibira, D., Kitutu, F. E., Merrett, G. B., & Mantel-Teeuwisse, A. K. (2017). Availability, prices and affordability of UN Commission's lifesaving medicines for reproductive and maternal health in Uganda. Journal of Pharmaceutical Policy and Practice, 10(1), Article 35. [DOI] [Repository]
Sagwa, E. L., Ruswa, N., Mavhunga, F., Rennie, T., Mengistu, A., Mekonen, T. T., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2017). Renal function of MDR-TB patients treated with kanamycin regimens or concomitantly with antiretroviral agents. International Journal of Tuberculosis and Lung Disease, 21(12), 1245-1250. [DOI] [Repository]
Minnema, L. A., Giezen, T. J., Gardarsdottir, H., Egberts, T. C. G., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2017). Post-marketing label changes in dosing information of biopharmaceuticals-different from small molecules? Pharmacoepidemiology and Drug Safety, 26, 606-607. [DOI]
van de Garde, E. M. W., van Wessel, T., Teeuwisse, A. K., & Steenman, S. C. (2017). Selectie of 'gewongen matching' in de master: Identificeren van instrumenten die studiesucces kunnen voorspellen bij Farmacie. Onderzoek van Onderwijs, 46(2), 8-12. https://www.tijdschriftovo.nl/art/50-4615_Selectie-of-gedwongen-matching-in-de-master-identificeren-van-instrumenten-die-studiesucces-kunnen-voorspellen-bij-Farmacie [Repository]
Van Den Heuvel, J. M., Hövels, A. M., Büller, H. R., Mantel-Teeuwisse, A. K., De Boer, A., & Maitland-Van Der Zee, A. H. (2017). Noacs replace VKA as preferred oral anticoagulant among new patients. Pharmacoepidemiology and Drug Safety, 26, 565-566. [DOI] [Repository]
Sagwa, E. L., Souverein, P. C., Ribeiro, I., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2017). Differences in VigiBase® reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment. Pharmacoepidemiology and Drug Safety, 26(1), 1-8. [DOI] [Repository]
Lilih, S., Pereboom, M., van der Hoeven, R. T. M., Mantel-Teeuwisse, A. K., & Becker, M. L. (2017). Improving the effectiveness of drug safety alerts to increase adherence to the guideline for gastrointestinal prophylaxis. International Journal of Medical Informatics, 97, 139-144. [DOI] [Repository]
Vranken, M. J. M., Mantel-Teeuwisse, A. K., Jünger, S., Radbruch, L., Scholten, W., Lisman, J. A., Subataite, M., & Schutjens, M.-H. D. B. (2017). Barriers to access to opioid medicines for patients with opioid dependence: a review of legislation and regulations in eleven central and eastern European countries. Addiction (Abingdon, England), 112(6), 1069-1076. [DOI] [Repository]
Ivanovska, V., Leufkens, H. G., Rademaker, C. M., Zisovska, E., Pijnenburg, M. W., van Dijk, L., & Mantel-Teeuwisse, A. K. (2017). Are age-appropriate antibiotic formulations missing from the WHO list of essential medicines for children? A comparison study. Archives of Disease in Childhood, 102(4), 352-356. [DOI] [Repository]
Vargas-Peláez, C. M., Soares, L., Rover, M. R. M., Blatt, C. R., Mantel-Teeuwisse, A., Rossi Buenaventura, F. A., Restrepo, L. G., Latorre, M. C., López, J. J., Bürgin, M. T., Silva, C., Leite, S. N., & Mareni Rocha, F. (2017). Towards a theoretical model on medicines as a health need. Social Science and Medicine, 178, 167-174. [DOI] [Repository]
Ankrah, D. N. A., Lartey, M., Mantel-Teeuwisse, A. K., & Leufkens, H. G. M. (2017). Five-year trends in treatment changes in an adult cohort of HIV/AIDS patients in Ghana: a retrospective cohort study. BMC Infectious Diseases, 17(1), Article 664. [DOI] [Repository]
Other output
Bloem, L. T., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., De Bruin, M. L., Klungel, O. H., & Hoekman, J. (2017). Risk factors associated with post-marketing changes in specific obligations of conditionally authorised products in the EU. Pharmacoepidemiology and Drug Safety, 26, 605. [DOI]
2016
Scholarly publications
Vogler, S., Zimmermann, N., Ferrario, A., Wirtz, V. J., de Joncheere, K., Pedersen, H. B., Dedet, G., Paris, V., Mantel-Teeuwisse, A. K., Babar, Z.-U.-D., & Scientific Programme Committee of the 2015 PPRI Conference (2016). Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference. Journal of Pharmaceutical Policy and Practice, 9, Article 9. [DOI] [Repository]
Tetteh, R. A., Nartey, E. T., Lartey, M., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., Yankey, B. A., & Dodoo, A. N. O. (2016). Association Between the Occurrence of Adverse Drug Events and Modification of First-Line Highly Active Antiretroviral Therapy in Ghanaian HIV Patients. Drug Safety, 39(11), 1139-1149. [DOI] [Repository]
Santa Ana Tellez, Y., Teeuwisse, A. K., Leufkens, H. G. M., & Wirtz, V. J. (2016). Effects of over-the-counter sales restriction of antibiotics on substitution with medicines for symptoms relief of cold in Mexico and Brazil: time series analysis. Health Policy and Planning, 31(9), 1291-1296. [DOI] [Repository]
Sagwa, E., Ruswa, N. C., Mavhunga, F., Rennie, T., Leufkens, H. G. M., & Teeuwisse, A. K. (2016). Adverse events and patients' perceived health-related quality of life at the end of multidrug-resistant tuberculosis treatment in Namibia. Patient Preference and Adherence, 2016(10), 2369-2377. [DOI] [Repository]
Ivanovska, V., Hek, K., Teeuwisse, A. K., Leufkens, H. G. M., Nielen, M. M., & van Dijk, L. (2016). Antibiotic prescribing for children in primary care and adherence to treatment guidelines. Journal of Antimicrobial Chemotherapy, 71(6), 1707-1714. [DOI] [Repository]
Ankrah, D., Koster, E. S., Teeuwisse, A. K., Arhinful, D. K., Agyepong, I. A., & Lartey, M. (2016). Facilitators and barriers to antiretroviral therapy adherence among adolescents in Ghana. Patient Preference and Adherence, 10, 329—337. [DOI] [Repository]
Hoekman, J., Klamer, T. T., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., & De Bruin, M. L. (2016). Characteristics and follow-up of postmarketing studies of conditionally authorized medicines in the EU. British Journal of Clinical Pharmacology, 82(1), 213-226. [DOI] [Repository]
Ebbers, H. C., Tienda, N. F. D., Hoefnagel, M. C., Nibbeling, R., & Mantel-Teeuwisse, A. K. (2016). Characteristics of product recalls of biopharmaceuticals and small-molecule drugs in the USA. Drug Discovery Today, 21(4), 536–539. [DOI] [Repository]
Vranken, M. J. M., Lisman, J. A., Mantel-Teeuwisse, A. K., Jünger, S., Scholten, W., Radbruch, L., Payne, S., & Schutjens, M.-H. D. B. (2016). Barriers to access to opioid medicines: a review of national legislation and regulations of 11 central and eastern European countries. Lancet Oncology, 17(1), e13-22. [DOI] [Repository]
Langedijk, J., Whitehead, C. J., Slijkerman, D. S., Leufkens, H. G. M., Schutjens, M.-H. D. B., & Mantel-Teeuwisse, A. K. (2016). Extensions of indication throughout the drug product lifecycle: a quantitative analysis. Drug Discovery Today, 21(2), 348–355. [DOI] [Repository]
Langedijk, J., Ebbers, H. C., Mantel-Teeuwisse, A. K., Kruger-Peters, A. G., & Leufkens, H. G. M. (2016). Licensing failure in the European decentralised procedure. European Journal of Pharmaceutical Sciences, 87, 47–51. [DOI] [Repository]
Fazeli Farsani, S., Souverein, P. C., van der Vorst, M. M. J., Knibbe, C. A. J., Herings, R. M. C., de Boer, A., & Mantel-Teeuwisse, A. K. (2016). Increasing trends in the incidence and prevalence rates of type 1 diabetes among children and adolescents in the Netherlands. Pediatric Diabetes, 17(1), 44–52. [DOI] [Repository]
Professional publications
Hek, K., Ivanovska, V., Mantel-Teeuwisse, A., & van Dijk, L. (2016). Voorschrijven van antibiotica bij kinderen. Huisarts en Wetenschap, 59(9), 410. [DOI] [Repository]
Blom, L., Winters, N., Mantet-Teeuwisse, A., & Bouvy, M. (2016). Stagelopen in de apotheek vereist kwaliteit van opleider: UPPER-beleid voor opleidingsapotheken in de openbare farmacie . Pharmaceutisch Weekblad, 151(50), 10-13. https://www.pw.nl/achtergrond/2016/stagelopen-in-de-apotheek-vereist-kwaliteit-van-opleider
Other output
Fazeli Farsani, S., Abdullah-Koolmees, H., Souverein, P. C., De Boer, A., & Mantel-Teeuwisse, A. K. (2016). Psychiatric medication use before and after the onset of type 1 diabetes in children and adolescents: A population-based cohort study. Pharmacoepidemiology and Drug Safety, 25(S3), 175-176. [DOI]
2015
Scholarly publications
Fazeli Farsani, S., Souverein, P. C., Overbeek, J. A., van der Vorst, M. M. J., Knibbe, C. A. J., Herings, R. M. C., de Boer, A., & Mantel-Teeuwisse, A. K. (2015). Long term trends in oral antidiabetic drug use among children and adolescents in the Netherlands. British Journal of Clinical Pharmacology, 80(2), 294-303. [DOI] [Repository]
Tetteh, R. A., Nartey, E. T., Lartey, M., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., Nortey, P. A., & Dodoo, A. N. O. (2015). Adverse events and adherence to HIV post-exposure prophylaxis: a cohort study at the Korle-Bu Teaching Hospital in Accra, Ghana. BMC Public Health, 15(573). [DOI] [Repository]
Santa-Ana-Tellez, Y., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., & Wirtz, V. J. (2015). Reply to "decrease in penicillin sales in Brazil after over-the-counter restrictions". Antimicrobial Agents and Chemotherapy, 59(9), 5864. [DOI] [Repository]
Bazargani, Y. T., de Boer, A., Schellens, J. H. M., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2015). Essential medicines for breast cancer in low and middle income countries. BMC Cancer, 15(591). [DOI] [Repository]
Vermeer, N. S., Straus, S. M. J. M., Mantel-Teeuwisse, A. K., Hidalgo-Simon, A., Egberts, A. C. G., Leufkens, H. G. M., & De Bruin, M. L. (2015). Drug-induced progressive multifocal leukoencephalopathy: Lessons learned from contrasting natalizumab and rituximab. Clinical Pharmacology and Therapeutics, 98(5), 542-550. [DOI] [Repository]
Sagwa, E. L., Ruswa, N., Mavhunga, F., Rennie, T., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2015). Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort. BMC pharmacology & toxicology, 16(36). [DOI] [Repository]
Fazelifarsani, S., Souverein, P. C., van der Vorst, M. M. J., Knibbe, C. A. J., de Boer, A., & Mantel-Teeuwisse, A. K. (2015). Chronic comorbidities in children with type 1 diabetes: a population-based cohort study. Archives of Disease in Childhood, 100(8), 763-8. [DOI] [Repository]
Langedijk, J., Mantel-Teeuwisse, A. K., Slijkerman, D. S., & Schutjens, M.-H. D. B. (2015). Drug repositioning and repurposing: terminology and definitions in literature. Drug Discovery Today, 20(8), 1027-1034. [DOI] [Repository]
Santa-Ana-Tellez, Y., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., & Wirtz, V. J. (2015). Seasonal Variation in Penicillin Use in Mexico and Brazil: Analysis of the Impact of Over-the-Counter Restrictions. Antimicrobial Agents and Chemotherapy, 59(1), 105-10. [DOI] [Repository]
Vermeer, N. S., Spierings, I., Mantel-Teeuwisse, A. K., Straus, S. M., Giezen, T. J., Leufkens, H. G., Egberts, T. C., & De Bruin, M. L. (2015). Traceability of biologicals: present challenges in pharmacovigilance. Expert Opinion on Drug Safety, 14(1), 63-72. [DOI] [Repository]
Professional publications
Farsani, S. F., & Mantel-Teeuwisse, A. K. (2015). Diabetes vergroot ook bij kind de kans op chronische ziekte. Pharmaceutisch Weekblad, 150(36), 18-21. [Repository]
2014
Scholarly publications
Meneses Leonardo Alves, T., Martins de Freitas, A. F., van Eijk, M. E. C., & Mantel-Teeuwisse, A. K. (2014). Compliance of disease awareness campaigns in printed Dutch media with national and international regulatory guidelines. PLoS One, 9(9), e106599. [DOI]
Taghipour Bazargani, Y., de Boer, A., Schellens, J. H. M., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2014). Selection of oncology medicines in low- and middle-income countries. Annals of Oncology, 25(1), 270-276. [DOI]
Fazelifarsani, S., Souverein, P. C., van der Vorst, M. M. J., Mantel-Teeuwisse, A. K., Knibbe, C. A. J., & de Boer, A. (2014). Disease history and medication use as risk factors for the clinical manifestation of type 1 diabetes in children and young adults: an explorative case control study. PLoS One, 9(2), e87408. [DOI] [Repository]
Taghipour Bazargani, Y., Ewen, M., de Boer, A., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2014). Essential medicines are more available than other medicines around the globe. PLoS One, 9(2), Article e87576. [DOI] [Repository]
Taghipour Bazargani, Y., de Boer, A., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2014). Essential medicines for COPD and asthma in low and middle-income countries. Thorax, 69(12), 1149-51. [DOI]
Vranken, M. J. M., Mantel-Teeuwisse, A. K., Jünger, S., Radbruch, L., Lisman, J., Scholten, W., Payne, S., Lynch, T., & Schutjens, M.-H. D. B. (2014). Legal Barriers in Accessing Opioid Medicines: Results of the ATOME Quick Scan of National Legislation of Eastern European Countries. Journal of Pain and Symptom Management, 48(6), 1135-44. [DOI]
Fazeli Farsani, S., Souverein, P. C., van der Vorst, M. M. J., Knibbe, C. A. J., de Boer, A., & Mantel - Teeuwisse, A. (2014). Population-based cohort study of anti-infective medication use before and after the onset of type 1 diabetes in children and adolescents. Antimicrobial Agents and Chemotherapy, 58(8), 4666-4674. [DOI] [Repository]
Ivanovska, V., Rademaker, C. M. A., van Dijk, L., & Mantel-Teeuwisse, A. K. (2014). Pediatric drug formulations: a review of challenges and progress. Pediatrics, 134(2), 361-72. [DOI]
Leopold, C., Zhang, F., Mantel-Teeuwisse, A. K., Vogler, S., Valkova, S., Ross-Degnan, D., & Wagner, A. K. (2014). Impact of pharmaceutical policy interventions on utilization of antipsychotic medicines in Finland and Portugal in times of economic recession: interrupted time series analyses. International Journal for Equity in Health, 13, Article 13:53. [DOI] [Repository]
Taghipour Bazargani, Y., de Boer, A., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2014). Selection of essential medicines for diabetes in low and middle income countries: a survey of 32 national essential medicines lists. PLoS One, 9(9), Article e106072. [DOI] [Repository]
Leopold, C., Mantel-Teeuwisse, A. K., Vogler, S., Valkova, S., de Joncheere, K., Leufkens, H. G. M., Wagner, A. K., Ross-Degnan, D., & Laing, R. (2014). Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries. Bulletin of the World Health Organization, 92(9), 630-640D. [DOI]
Sagwa, E. L., Mantel-Teeuwisse, A. K., & Ruswa, N. C. (2014). Occurrence and clinical management of moderate-to-severe adverse events during drug-resistant tuberculosis treatment: a retrospective cohort study. Journal of Pharmaceutical Policy and Practice, 7(1), Article 14. [DOI] [Repository]
Hernandez, J. F., van Thiel, G. J. M. W., Mantel-Teeuwisse, A. K., Raaijmakers, J. A. M., & Pieters, T. (2014). Restoring trust in the pharmaceutical sector on the basis of the SSRI case. Drug Discovery Today, 19(5), 523-527. [DOI]
Vermeer, N. S., Duijnhoven, R. G., Straus, S. M. J. M., Mantel - Teeuwisse, A. K., Arlett, P. R., Egberts, A. C. G., Leufkens, H. G. M., & De Bruin, M. L. (2014). Risk management plans as a tool for proactive pharmacovigilance: a cohort study of newly approved drugs in europe. Clinical Pharmacology and Therapeutics, 96(6), 723-31. [DOI]
Other output
Fazelifarsani, S., Souverein, P. C., Van Der Vorst, M. M. J., Knibbe, C. A. J., De Boer, A., & Mantel-Teeuwisse, A. K. (2014). Chronic comorbidities in children and adolescents with type 1 diabetes. Pharmacoepidemiology and Drug Safety, 23(S1), 185. Article 351. [DOI] [Repository]
Taghipour Bazargani, Y., De Boer, A., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2014). Endocrine therapy for breast cancer patients in South Africa. Pharmacoepidemiology and Drug Safety, 23(S1), 70-71. Article 130. [DOI] [Repository]
Fazelifarsani, S., Souverein, P. C., Van Der Vorst, M. M. J., Knibbe, C. A. J., Herings, R. M. C., De Boer, A., & Mantel-Teeuwisse, A. K. (2014). Increasing trend of type 1 diabetes in Dutch children and adolescents (1998-2010). Pharmacoepidemiology and Drug Safety, 23(S1), 184. Article 349. [DOI] [Repository]
2013
Scholarly publications
Vermeer, N., Duijnhoven, R., Straus, S., Blackburn, S., Hoogendoorn, L., Mantel-Teeuwisse, A., Egberts, T., Leufkens, H., & De Bruin, M. (2013). Development of safety concerns within RMPs after approval: A cohort study of biologicals. Drug Safety, 36(9), 908-909. [DOI]
Hoebert, J. M., Irs, A., Mantel-Teeuwisse, A. K., & Leufkens, H. G. M. (2013). Future of the European Union regulatory network in the context of the uptake of new medicines. British Journal of Clinical Pharmacology, 76(1), 1-6. [DOI]
Ebbers, H. C., Mantel-Teeuwisse, A. K., Sayed-Tabatabaei, F. A., Moors, E. H. M., Schellekens, H., & Leufkens, H. G. M. (2013). The role of Periodic Safety Update Reports in the safety management of biopharmaceuticals. European Journal of Clinical Pharmacology, 69(2), 217-226. [DOI] [Repository]
Crijns, I., Mantel-Teeuwisse, A., Bloemberg, R., Pinas, E., Straus, S., & de Jong-van den Berg, L. (2013). Healthcare professional surveys to investigate the implementation of the isotretinoin Pregnancy Prevention Programme: a descriptive study. Expert Opinion on Drug Safety, 12(1), 29-38. [DOI]
Hoebert, J. M., van Dijk, L., Mantel-Teeuwisse, A. K., Leufkens, H. G., & Laing, R. O. (2013). National medicines policies - a review of the evolution and development processes. Journal of Pharmaceutical Policy and Practice, 6, 5. [DOI]
Ebbers, H. C., Al-Temimi, E., Moors, E. H. M., Mantel-Teeuwisse, A. K., Schellekens, H., & Leufkens, H. G. M. (2013). Differences between post-authorization adverse drug reactions of biopharmaceuticals and small molecules. BioDrugs, 27(2), 167-174. [DOI] [Repository]
Ankrah, D. N. A., Mantel-Teeuwisse, A. K., De Bruin, M. L., Amoo, P. K., Ofei-Palm, C. N., Agyepong, I., & Leufkens, H. G. M. (2013). Incidence of adverse events among healthcare workers following H1N1 Mass immunization in Ghana: a prospective study. Drug Safety, 36(4), 259-66. [DOI]
Ebbers, H. C., van Meer, P. J. K., Moors, E. H. M., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., & Schellekens, H. (2013). Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab. Drug Discovery Today, 18(17-18), 872-879. [DOI] [Repository]
Jünger, S., Brearley, S., Payne, S., Mantel-Teeuwisse, A. K., Lynch, T., Scholten, W., & Radbruch, L. (2013). Consensus building on access to controlled medicines: a four-stage Delphi consensus procedure. Journal of Pain and Symptom Management, 46(6), 897-910. [DOI]
Vermeer, N. S., Straus, S. M. J. M., Mantel - Teeuwisse, A., Domergue, F., Egberts, T. C. G., Leufkens, H. G. M., & De Bruin, M. L. (2013). Traceability of biopharmaceuticals in spontaneous reporting systems: a cross-sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases. Drug Safety, 36(8), 617-25. [DOI]
Putzeist, M., Mantel-Teeuwisse, A. K., Llinares, J., Gispen-De Wied, C. C., Hoes, A. W., & Leufkens, H. G. M. (2013). EU marketing authorization review of orphan and non-orphan drugs does not differ. Drug Discovery Today, 18(19-20), 1001-6. [DOI]
Sagwa, E., Ruswa, N., Musasa, J. P., & Mantel-Teeuwisse, A. K. (2013). Adverse events during treatment of drug-resistant tuberculosis: a comparison between patients with or without human immunodeficiency virus co-infection. Drug Safety, 36(11), 1087-1096. [DOI]
Leopold, C., Mantel - Teeuwisse, A., Vogler, S., de Joncheere, K., Laing, R. O., & Leufkens, H. G. M. (2013). Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries. Health Policy, 112(3), 209-16. [DOI]
Santa-Ana-Tellez, Y., Mantel-Teeuwisse, A. K., Dreser, A., Leufkens, H. G. M., & Wirtz, V. J. (2013). Impact of over-the-counter restrictions on antibiotic consumption in Brazil and Mexico. PLoS One, 8(10), e75550. [DOI]
Tetteh, R. A., Nartey, E. T., Lartey, M., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., Nortey, P. A., & Dodoo, A. N. O. (2013). Outcomes of a Postexposure Prophylaxis Program at the Korle-Bu Teaching Hospital in Ghana: A Retrospective Cohort Study. Journal of the International Association of Providers of AIDS Care, 14(6), 544-52. [DOI]
Putzeist, M., Mantel-Teeuwisse, A. K., Wied, C. C. G., Hoes, A. W., Leufkens, H. G. M., & de Vrueh, R. L. A. (2013). Drug development for exceptionally rare metabolic diseases: challenging but not impossible. Orphanet Journal of Rare Diseases, 8, 179. [DOI]
Leopold, C., Vogler, S., Habl, C., Mantel-Teeuwisse, A. K., & Espin, J. (2013). Personalised medicine as a challenge for public pricing and reimbursement authorities – A survey among 27 European countries on the example of trastuzumab. Health Policy, 113(3), 313-22.
Wangge, G., Putzeist, M., Knol, M. J., Klungel, O. H., Gispen-De Wied, C. C., de Boer, A., Hoes, A. W., Leufkens, H. G., & Mantel-Teeuwisse, A. K. (2013). Regulatory Scientific Advice on Non-Inferiority Drug Trials. PLoS One, 8(9), Article e74818. [DOI]
Kaplan, W., Wirtz, V. J., Mantel-Teeuwisse, A. K., Stolk, P., Duthey, B., & Laing, R. O. (2013). Priority Medicines for Europe and the World 2013 Update. World Health Organization.
2012
Scholarly publications
Giezen, T. J., Mantel-Teeuwisse, A. K., Straus, S. M. J. M., Leufkens, H. G. M., & Egberts, T. C. G. (2012). Ander type bijwerkingen: Veiligheid biologicals vanuit regulatoir en klinisch perspectief. Pharmaceutisch Weekblad, 147(6), 15-17.
Leopold, C., Vogler, S., Mantel-Teeuwisse, A. K., de Joncheere, K., Leufkens, H. G. M., & Laing, R. (2012). Differences in external price referencing in Europe: a descriptive overview. Health Policy, 104(1), 50-60. [DOI]
Hoebert, J. M., Mantel-Teeuwisse, A. K., van Dijk, L., Bijlsma, J. W. J., & Leufkens, H. G. M. (2012). Do rheumatoid arthritis patients have equal access to treatment with new medicines? tumour necrosis factor-alpha inhibitors use in four European countries. Health Policy, 104(1), 76-83. [DOI]
Hueskes, B. A. A., Roovers, E. A., Mantel-Teeuwisse, A. K., Janssens, H. J. E. M., van de Lisdonk, E. H., & Janssen, M. (2012). Use of diuretics and the risk of gouty arthritis: a systematic review. Seminars in Arthritis & Rheumatism, 41(6), 879-889. [DOI]
Ebbers, H. C., Mantel-Teeuwisse, A. K., Moors, E. H. M., Sayed Tabatabaei, F. A., Schellekens, H., & Leufkens, H. G. M. (2012). A cohort study exploring determinants of safety-related regulatory actions for biopharmaceuticals. Drug Safety, 35(5), 417-427. [DOI] [Repository]
Radbruch, L., Jünger, S., Mantel-Teeuwisse, A., Gilson, A., Cleary, J., Payne, S., & Scholten, W. (2012). Re: Ensuring patient access to essential medicines while minimizing harmful use: a revised World Health Organization tool to improve national drug control policy. Letter to the editor. Journal of Pain & Palliative Care Pharmacotherapy, 26(2), 200-201. [DOI]
Cameron, A., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., & Laing, R. O. (2012). Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved? Value in Health, 15(5), 664-73. [DOI]
Hernandez, J. F., Mantel-Teeuwisse, A. K., van Thiel, G. J. M. W., Belitser, S. V., Warmerdam, J., de Valk, V., Raaijmakers, J. A. M., & Pieters, T. (2012). A 10-year analysis of the effects of media coverage of regulatory warnings on antidepressant use in The Netherlands and UK. PLoS One, 7(9), e45515. [DOI]
Willemen, M. J. C., Mantel-Teeuwisse, A. K., Buggy, Y., Layton, D., Straus, S. M. J. M., Leufkens, H. G. M., & Egberts, T. C. G. (2012). Reasons for and time to discontinuation of rimonabant therapy: a modified prescription-event monitoring study. Drug Safety, 35(12), 1147-58. [DOI]
Giezen, T. J., Mantel-Teeuwisse, A. K., ten Berg, M. J., Straus, S. M. J. M., Leufkens, H. G. M., van Solinge, W. W., & Egberts, T. C. G. (2012). Rituximab-induced thrombocytopenia: a cohort study. European Journal of Haematology, 89(3), 256-66. [DOI]
Hueskes, B. A. A., Willems, F. F., Leen, A. C., Ninaber, P. A., Westra, R., Mantel-Teeuwisse, A. K., Janssens, H. J. E. M., van de Lisdonk, E. H., Roovers, E. A., & Janssen, M. (2012). A case-control study of determinants for the occurrence of gouty arthritis in heart failure patients. European Journal of Heart Failure, 14(8), 916-921. [DOI]
Sagwa, E., Mantel-Teeuwisse, A. K., Ruswa, N., Musasa, J. P., Pal, S., Dhliwayo, P., & van Wyk, B. (2012). The burden of adverse events during treatment of drug-resistant tuberculosis in Namibia. Southern Med Review, 5(1), 6-13.
Narsai, K., Williams, A., & Mantel-Teeuwisse, A. K. (2012). Impact of regulatory requirements on medicine registration in African countries - perceptions and experiences of pharmaceutical companies in South Africa. Southern Med Review, 5(1), 31-7.
Putzeist, M., Mantel-Teeuwisse, A. K., Aronsson, B., Rowland, M., Gispen-de Wied, C. C., Vamvakas, S., Hoes, A. W., Leufkens, H. G. M., & Eichler, H.-G. (2012). Factors influencing non-approval of new drugs in Europe. Nature Reviews. Drug Discovery, 11(12), 903-904. [DOI]
Leopold, C., Mantel-Teeuwisse, A. K., Seyfang, L., Vogler, S., de Joncheere, K., Laing, R. O., & Leufkens, B. (2012). Impact of external price referencing on medicine prices - a price comparison among 14 European countries. Southern Med Review, 5(2), 34-41.
Putzeist, M., Heemstra, H. E., Garcia, J. L., Mantel-Teeuwisse, A. K., Gispen-de Wied, C. C., Hoes, A. W., & Leufkens, H. G. M. (2012). Determinants for successful marketing authorisation of orphan medicinal products in the EU. Drug Discovery Today, 17(7/8), 352-358. http://www.ncbi.nlm.nih.gov/pubmed/22094244
Cameron, A., Bansai, A., Dua, T., Hill, S. R., Moshe, S. L., Mantel-Teeuwisse, A. K., & Saxena, S. (2012). Mapping the availability, price, and affordability of antiepileptic drugs in 46 countries. Epilepsia, 53(6), 962-969.
Narsai, K., Williams, A., & Mantel-Teeuwisse, A. K. (2012). Impact of regulatory requirements on medicine registration in African countries - perceptions and experiences of phamaceutical companies in South Africa. Southern Med Review, 5(1), 31-37.
Hoebert, J. M., Souverein, P. C., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., & van Dijk, C. E. M. J. (2012). Reimbursement Restriction and Moderate Decrease in Benzodiazepine Use in General Practice. Annals of Family Medicine, 10, 42-49.
Professional publications
Hoebert, J., Souverein, P., Mantel-Teeuwisse, A., Leufkens, H., & Van Dijk, L. (2012). Benzodiazepinegebruik daalt als de gebruiker zelf betaalt. Huisarts en Wetenschap, 55(7), 286-288. [DOI]
Other output
Ebbers, H. C., Al-Temimi, E., Moors, E. H., Mantel-Teeuwisse, A. K., Schellekens, H., & Leufkens, H. G. (2012). A comparison of post-authorization adverse events of biopharmaceuticals and small molecules within the same anatomical therapeutic chemical class. Pharmacoepidemiology and Drug Safety, 21(S3), 43. Article 85. [DOI]
Hernandez, J. F., Mantel-Teeuwisse, A. K., Van Thiel, G., Belitser, S., Warmerdam, J., De Valk, V., Raaijmakers, J., & Pieters, T. (2012). Long-term effects of regulatory warnings and increased media coverage on paroxetine and other SSRIs use. Pharmacoepidemiology and Drug Safety, 21(S3), 430. Article 928. [DOI]
Ebbers, H. C., Al-Temimi, E., Moors, E. H. M., Mantel-Teeuwisse, A. K., Schellekens, H., & Leufkens, H. G. (2012). A comparison of post-authorization adverse events of biopharmaceuticals and small molecules. Abstract from WHO Winter Meeting 2012, Utrecht, The Netherlands.
2011
Scholarly publications
Vermeer, N. S., Straus, S. M., Mantel Teeuwisse, A. K., Egberts, T. C., Leufkens, H. G., & De Bruin, M. L. (2011). Sparse batch number reporting for biologicals in FDA's adverse event reporting system (AERS). Drug Safety, 34(10), 1002.
Putzeist, M., Mantel-Teeuwisse, A. K., Gispen-De Wied, C. C., Hoes, A. W., & Leufkens, H. G. (2011). Regulatory scientific advice in drug development: does company size make a difference? European Journal of Clinical Pharmacology, 67(2), 157-164. [DOI]
Willemen, M. J., Mantel-Teeuwisse, A. K., Straus, S. M., Meijboom, R., Egberts, T. C., & Leufkens, H. G. (2011). Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care, 34(2), 369-74. [DOI]
Hoebert, J. M., Mantel-Teeuwisse, A. K., van Dijk, L., Laing, R. O., & Leufkens, H. G. M. (2011). Quality and completeness of utilisation data on biological agents across European countries: tumour necrosis factor alpha inhibitors as a case study. Pharmacoepidemiology and Drug Safety, 20(3), 265-71. [DOI]
Ebbers, H. C., Mantel-Teeuwisse, A. K., Moors, E. H. M., Schellekens, H., & Leufkens, H. G. (2011). Today's challenges in pharmacovigilance: what can we learn from epoetins? Drug Safety, 34(4), 273-287. [DOI] [Repository]
Hernandez, J. F., Mantel-Teeuwisse, A. K., van Thiel, G. J. M. W., Belitser, S. V., Raaijmakers, J. A. M., & Pieters, T. (2011). Publication trends in newspapers and scientific journals for SSRIs and suicidality: a systematic longitudinal study. BMJ Open, 1(2), e000290. [DOI]
Cameron, A., Roubos, I., Ewen, M., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., & Laing, R. O. (2011). Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. Bulletin of the World Health Organization, 89(6), 412-21.
Other output
Hernandez, J. F., Mantel-Teeuwisse, A. K., Van Thiel, G. J. M. W., Raaijmakers, J. A. M., & Pieters, T. (2011). Divergences between reports in scientific journals and newspapers on the role of SSRIs in suicide risk: A longitudinal study in the Netherlands (NL) and United Kingdom (UK) - 2000-2009. Pharmacoepidemiology and Drug Safety, 20(S1), S212-S213. Article 487. [DOI]
2010
Scholarly publications
Heemstra, H. E., Giezen, T. J., Mantel-Teeuwisse, A. K., de Vrueh, R. L. A., & Leufkens, H. G. M. (2010). Veiligheidswaarschuwingen voor weesgeneesmiddelen in de Europese Unie en de Verenigde Staten. Pharmaceutisch Weekblad, 145(29-30), 136-142.
Heemstra, H. E., Giezen, T. J., Mantel-Teeuwisse, A. K., de Vrueh, R. L. A., & Leufkens, H. G. M. (2010). Safety-related regulatory actions for orphan drugs in the US and EU: a cohort study. Drug Safety, 33(2), 127-37. [DOI]
Milder, I. E. J., Klungel, O. H., Mantel-Teeuwisse, A. K., Verschuren, W. M. M., & Bemelmans, W. J. E. (2010). Relation between body mass index, physical inactivity and use of prescription drugs: the Doetinchem Cohort Study. International Journal of Obesity, 34(6), 1060-9. [DOI]
Giezen, T. J., Mantel-Teeuwisse, A. K., Meijboom, R., Straus, S. M. J. M., Leufkens, H. G. M., & Egberts, T. C. G. (2010). Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase. Drug Safety, 33(10), 865-78. [DOI]
Ebbers, H. C., Mantel-Teeuwisse, A. K., Sayed Tabatabaei, F. A., Moors, E. H. M., Schellekens, H., & Leufkens, H. G. M. (2010). The contribution of periodic safety reports (PSURs) to safety related regulatory actions of biopharmaceuticals. Drug Safety, 33(10), 919. [DOI] [Repository]
Geleedst- de Vooght, M., Maitland-van der Zee, A. H., Schalekamp, T., Mantel-Teeuwisse, A. K., & Jansen, P. A. F. (2010). Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend study. Drugs & Aging, 27(7), 589-596. [DOI]
Other output
Hoebert, J. M., Mantel-Teeuwisse, A. K., van Dijk, C. E. M. J., & Leufkens, H. G. M. (2010). Critical Issues in Comparing the Use of Biologicals across Various European Countries: TNF Inhibitors as Case Study. S184. Abstract from Abstracts of the 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 19-22 August 2010, Brighton, UK.
Willemen, M. J. C., Mantel, A. K., Straus, S. M. J. M., Egberts, A. C. G., & Leufkens, H. G. M. (2010). DPP-4 Inhibitors and the Occurrence of Infections A Nested Case-Control Study. S168, S 395. Abstract from Abstracts of the 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 19-22 August 2010, Brighton, UK.
Willemen, M. J. C., Mantel, A. K., Straus, S. M. J. M., Leufkens, H. G. M., & Egberts, A. C. G. (2010). Lifestyle Drugs and Psychiatric Adverse Events in Randomised Clinical Trials. S180, 424. Abstract from Abstracts of the 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 19-22 August 2010, Brighton, UK.
Giezen, T. J., Mantel-Teeuwisse, A. K., Straus, S. M. J. M., Leufkens, H. G. M., & Egberts, A. C. G. (2010). Evaluation of a Proposed Classification System for Adverse Drug Reactions for Biologicals Using The WHO-ADR Database VigiBase. S126, 295. Abstract from Abstracts of the 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 19-22 August 2010, Brighton, UK.
2009
Scholarly publications
Ramcharan, A. S., Van Stralen, K. J., Snoep, J. D., Mantel-Teeuwisse, A. K., Rosendaal, F. R., & Doggen, C. J. M. (2009). HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. Journal of Thrombosis and Haemostasis, 7(4), 514-520. [DOI]
Willemen, M. J. C., Mantel-Teeuwisse, A. K., Straus, S. M. J. M., Leufkens, H. G. M., Egberts, A. C. G., & Sturkenboom, M. C. J. M. (2009). Cardiovascular and psychiatric risk profile and patterns of use in patients starting anti-obesity drugs. Pharmacoepidemiology and Drug Safety, 18(7), 631-8. [DOI]
Giezen, T. J., Mantel-Teeuwisse, A. K., & Leufkens, H. G. M. (2009). Pharmacovigilance of biopharmaceuticals: challenges remain. Drug Safety, 32(10), 811-7. [DOI]
Giezen, T. J., Mantel-Teeuwisse, A. K., Straus, S. M. J. M., Egberts, T. C. G., Blackburn, S., Persson, I., & Leufkens, H. G. M. (2009). Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval. Drug Safety, 32(12), 1175-87. [DOI]
Giezen, T. J., Straus, S. M. J. M., & Mantel-Teeuwisse, A. K. (2009). Pharmacovigilance of Biosimilars from a regulatory point of view: Is there a need for a specific approach? The international journal of risk and safety in medicine, 21, 53-58.
Other output
Giezen, T. J., Mantel-Teeuwisse, A. K., Straus, S. M. J. M., Meijboom, R. H. B., Leufkens, H. G. M., & Egberts, A. C. G. (2009). Unraveling the safety profile of biologicals using postmarketing safety data. Drug Safety, 32(10), 966.
2008
Scholarly publications
Giezen, T. J., Mantel-Teeuwisse, A. K., Straus, S. M. J. M., Schellekens, H., Leufkens, H. G. M., & Egberts, A. C. G. (2008). Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA - The Journal of The American Medical Association, 300(16), 1887-1896. [DOI]
Willemen, M. J., Mantel-Teeuwisse, A. K., Straus, S. M. J. M., Leufkens, H. G., & Egberts, A. C. G. (2008). Psychiatric and Cardiovascular Comorbidities in Patients With Diabetes Mellitus Starting Antiobesity Drugs. Obesity Research, 16(10), 2331-2335.
Other output
Giezen, T. J., Mantel-Teeuwisse, A. K., Straus, S. M. J. M., Egberts, A. C. G., Persson, I., & Leufkens, H. G. M. (2008). Methodological Analysis of Post-Authorisation Safety Studies as Part of the First Cohort of Risk Management Plans: Small Molecules vs. Biologicals. S189. Abstract from 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management.
Giezen, T. J., Mantel-Teeuwisse, A. K., Straus, S. M. J. M., Schellekens, H., & Leufkens, H. G. M. (2008). Safety Related Regulatory Actions for Biologicals Approved in the US and Europe Since 1995. S29. Abstract from 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management.
Willemen, M. J. C., Mantel-Teeuwisse, A. K., Straus, S. M. J. M., Egberts, A. C. G., Leufkens, H. G. M., & Sturkenboom, M. C. J. M. (2008). Patients Starting Anti-Obesity Drugs Carry Higher Psychiatric and Cardiovascular Risk. S178. Abstract from 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management.
2007
Scholarly publications
Gumbs, P. D., Verschuren, W. M. M., Souverein, P. C., Mantel-Teeuwisse, A. K., de Wit, G. A., de Boer, A., & Klungel, O. H. (2007). Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution. British Journal of Clinical Pharmacology, 64(5), 680-685. [DOI]
Gumbs, P. D., Verschuren, M. W. M., Mantel-Teeuwisse, A. K., de Wit, A. G., de Boer, A., & Klungel, O. H. (2007). Economic evaluations of cholesterol-lowering drugs: a critical and systematic review. PharmacoEconomics, 25(3), 187-199. [Repository]
Professional publications
Klungel, O. H., Mantel-Teeuwisse, A. K., & De Boer, T. (2007). Hypertensie en hypercholesterolemia over- en onderbehandeling vormen risico. Pharmaceutisch Weekblad, 142(14), 24-29.
Giezen, T., Straus, S., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., & Egberts, A. C. G. (2007). Risk management of biopharmaceuticals: a regulatory perspective. EJHP Practice, 13(6), 72-74. [Repository]
Other output
Willemen, M. J. C., Mantel-Teeuwisse, A. K., Straus, S. M. J. M., Leufkens, H. G. M., & Egberts, A. C. G. (2007). Characteristics of Diabetic Patients Starting Anti-Obesity Drugs. P.114. Abstract from ISoP.
Mantel-Teeuwisse, A. K., Straus, S. M. J. M., Lekkerkerker, J. F. F., & Schobben, A. F. A. M. (2007). Community Pharmacists' Adherence to the Isotretinoin Pregnancy Prevention Program in The Netherlands. O.14. Abstract from ISoP.
Giezen, T. J., Mantel-Teeuwisse, A. K., Straus, S. M. J. M., Schellekens, H., Egberts, A. C. G., & Leufkens, H. G. M. (2007). Safety Warning Issues for Biotechnology Derived Pharmaceuticals Approved Since 1995. P.115. Abstract from ISoP.
2006
Scholarly publications
Gumbs, P. D., Verschuren, W. M. M., Mantel-Teeuwisse, A. K., de Wit, G. A., Hofman, A., Trienekens, P. H., Stricker, B. H. C., de Boer, A., & Klungel, O. H. (2006). Drug costs associated with non-adherence to cholesterol management guidelines for primary prevention of cardiovascular disease in an elderly population: The Rotterdam Study. Drugs and Aging, 23(9), 733-741. [DOI]
Mantel-Teeuwisse, A. K., Klungel, O. H., Hofman, A., Verschuren, W. M. M., Trienekens, P. H., Porsius, A. J., Stricker, B. H. C., & de Boer, A. (2006). Prescribing behaviour according to Dutch and European guidelines on the management of hypercholesterolaemia (1992-1999). British Journal of Clinical Pharmacology, 61(5), 592-600. [DOI]
Professional publications
Mantel-Teeuwisse, A. K., & Klungel, O. H. (2006). Zijn cholesterolverlagende margarines werkzaam en is er een interactie met statines? Internisten Vademecum, 11(10). [Repository]
Other output
Mantel-Teeuwisse, A. K., van der Elst, M. E., Klungel, O. H., Bouvy, M. L., de Blaey, C. J., & de Boer, A. (2006). Acute Effects of Discontinuation of Statin Treatment on the Occurrence of a First Myocardial Infarction. S247. Abstract from Unknown event, Asilomar, USA.
2005
Scholarly publications
Gumbs, P. D., Verschuren, W. M. M., Mantel-Teeuwisse, A. K., De Boer, A., & Klungel, O. H. (2005). Medicamenteuze behandling van hypercholesterolemie kosteneffectief. Pharmaceutisch Weekblad, 140(32), 982-983.
Gumbs, P. D., Verschuren, W. M. M., Mantel-Teeuwisse, A. K., De Boer, A., & Klungel, O. H. (2005). Kosteneffectiviteit van statines. Pharmaceutisch Weekblad, 140(32), 982-983.
Mantel-Teeuwisse, A. K., Klungel, O. H., Schalekamp, T., Verschuren, W. M. M., Porsius, A. J., & de Boer, A. (2005). Suboptimal choices and dosing of statins at start of therapy. British Journal of Clinical Pharmacology, 60(1), 83-89. [Repository]
Professional publications
Mantel-Teeuwisse, A. K., & Klungel, O. H. (2005). Zijn Cholesterolverlagende margarines werkzaam en is er een interactie met statines? Apothekers vademecum, 1(6).
Mantel-Teeuwisse, A. K., & Klungel, O. H. (2005). Zijn cholesterolverlagende margarines werkzaam en is er een interactie met statines? Cardiologen Vademecum, 9(3). [Repository]
Gumbs, P. D., Verschuren, W. M. M., Mantel-Teeuwisse, A. K., de Boer, A., & Klungel, O. H. (2005). Medicamenteuze behandeling van hypercholesterolemie kosteneffectief. Pharmaceutisch Weekblad, 32, 982-983. [Repository]
2004
Scholarly publications
Mantel-Teeuwisse, A. K., Verschuren, W. M. M., Klungel, O. H., de Boer, A., & Kromhout, D. (2004). Recent trends in (under)treatment of hypercholesterolaemia in the Netherlands. British Journal of Clinical Pharmacology, 58(3), 310-316. [DOI] [Repository]
Mantel-Teeuwisse, A. K., Klungel, O. H., Egberts, T. C. G., Verschuren, W. M. M., Porsius, A. J., & de Boer, A. (2004). Failure to continue lipid-lowering drug use following the withdrawal of cerivastatin. Drug Safety, 27(1), 63-70. [Repository]
Mantel-Teeuwisse, A. K. (2004). Quality and safety aspects of lipid-lowering drug use. [Doctoral thesis 1 (Research UU / Graduation UU), Utrecht University].
Mantel-Teeuwisse, A. K., Goettsch, W. G., Klungel, O. H., de Boer, A., & Herings, R. M. C. (2004). Long term persistence with statin treatment in daily medical practice. Heart, 90(9), 1065-1066. [DOI] [Repository]
Professional publications
Mantel-Teeuwisse, A. K., & Klungel, O. H. (2004). Zijn cholesterol verlagende margarines werkzaam en is er een interactie met statines? Apothekers vademecum, 5(7). [Repository]
Maitland-van der Zee, A. H., & Mantel-Teeuwisse, A. K. (2004). Wat is de relevantie van de interactie tussen verapamil en simvastatine. Vademecum permanente nascholing huisartsen, 16(22). [Repository]
Other output
Mantel-Teeuwisse, A. K., Klungel, O. H., Hofman, A., Verschuren, W. M. M., Trienekens, P. H., Porsius, A. J., Stricker, B. H. C., & de Boer, A. (2004). The Need To Change Prescibing Behaviour According to Dutch and European Guidelines on the Management of Hypercholesterolemia. S28. Abstract from Unknown event, Asilomar, USA.
Mantel-Teeuwisse, A. K., Goettsch, W. G., Klungel, O. H., de Boer, A., & Herings, R. M. C. (2004). Determinants of persistence with statin use in daily medical practice. 361. Abstract from Unknown event, Asilomar, USA.
2003
Scholarly publications
Maitland-van der Zee, A.-H., Stricker, B. H. C., Klungel, O. H., Mantel-Teeuwisse, A. K., Kastelein, J. J. P., Hofman, A., Leufkens, H. G. M., van Duijn, C. M., & de Boer, A. (2003). Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes. Pharmacogenetics, 13(4), 219-223. [DOI]
Mantel-Teeuwisse, A. K., Verschuren, W. M. M., Klungel, O. H., Kromhout, D., Lindemans, A. D., Avorn, J., Porsius, A. J., & de Boer, A. (2003). Undertreatment of hypercholesterolaemia: a population-based study. British Journal of Clinical Pharmacology, 55, 389-397. [Repository]
Professional publications
Klungel, O. H., Mantel-Teeuwisse, A. K., & De Boer, A. (2003). Geslachtsverschillen in de epidemiologie, risico en behandeling. Farmacotherapie van hypertensie en hypercholesterolemie. Pharmaceutisch Weekblad, 138(40), 1383-1389.
Maitland-van der Zee, A. H., & Mantel-Teeuwisse, A. K. (2003). Is de relevantie van de interactie tussen Isoptin® (verapamil) en Zocor® (simvastatine)? Cardiologen Vademecum, 7(14).
Klungel, O. H., Mantel-Teeuwisse, A. K., & de Boer, A. (2003). Medicamenteuze behandeling van hypertensie en hypercholesterolemie. Sekseverschillen in epidemiologie, risico en therapie. Pharmaceutisch Weekblad, 138(40), 1383-1389. [Repository]
Maitland-van der Zee, A. H., & Mantel-Teeuwisse, A. K. (2003). Wat is de relavantie van de interactie tussen Isoptin® (verapamil) en Zocor® (simvastatine)? Apothekers vademecum, 4(7).
Other output
Mantel-Teeuwisse, A. K., Goettsch, W. G., Klungel, O. H., de Boer, A., & Herings, R. M. C. (2003). Discontinuation of Statin Use in Daily Medical Practice. S76. Abstract from Unknown event, Asilomar, USA.
de Boer, A., Herings, R. M. C., Mantel-Teeuwisse, A. K., Goettsch, W. G., & Klungel, O. H. (2003). Discontinuation of Satin Use in Daily Medical Practice. S76. Abstract from Unknown event, Asilomar, USA.
2002
Scholarly publications
Derijks, H. J., De Koning, G. H. P., Mantel-Teeuwisse, A. K., & Egberts, A. C. G. (2002). Limited adherence to safety instructions in drug leaflets [1]. British Journal of Clinical Pharmacology, 54(6), 678-679. [DOI]
Mantel-Teeuwisse, A. K., Klungel, O. H., Verschuren, W. M. M., Porsius, A. J., & De Boer, A. (2002). Time trends in lipid lowering drug use in the Netherlands. Has the backlog of candidates for treatment been eliminated? British Journal of Clinical Pharmacology, 53(4), 379-385. [DOI]
Derijks, H. J., de Koning, G. H. P., Mantel-Teeuwisse, A. K., & Egberts, A. C. G. (2002). Limited adherence to safety instructions in drug leaflets. British Journal of Clinical Pharmacology, 54, 678-683. [Repository]
Mantel-Teeuwisse, A. K., Klungel, O. H., Herings, R. M. C., van Puijenbroek, E. P., Porsius, A. J., & de Boer, A. (2002). Myopathy due to statin/fibrate use in the Netherlands. Annals of Pharmacotherapy, 36(12), 1957-1960.
Other output
Mantel-Teeuwisse, A. K., Klungel, O. H., Egberts, A. C. G., Verschuren, W. M. M., Porsius, A. J., & de Boer, A. (2002). Patterns of lipid lowering drug use after the withdrawal of cerivastatin. 234 P011-235. Abstract from Unknown event, Asilomar, USA.
Maitland-van der Zee, A. H., Stricker, B. H. C., Klungel, O. H., Mantel-Teeuwisse, A. K., Kastelein, J. J. P., Hofman, A., Leufkens, H. G. M., van Duijn, C. M., & de Boer, A. (2002). Adherence to and dosing of HMG-CoA reductase inhibitors differs according to apolipoprotein E-genotypes. s15. Abstract from Unknown event, Asilomar, USA.
Maitland-van der Zee, A. H., Stricker, B. H. C., Klungel, O. H., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., van Duijn, C. M., & de Boer, A. (2002). The use of statins in the general population differ according to APOE-genotypes. 559. Abstract from Unknown event, Asilomar, USA.
Mantel-Teeuwisse, A. K., Egberts, A. C. G., Klungel, O. H., Verschuren, W. M. M., Porsius, A. J., & de Boer, A. (2002). Patterns of lipid lowering drug use after the withdrawal of cerivastatin.. 559P. Abstract from Unknown event, Asilomar, USA.
Mantel-Teeuwisse, A. K., Verschuren, W. M. M., Klungel, O. H., Porsius, A. J., & de Boer, A. (2002). Determinants of undertreatment of hypercholesterolemia in a population-based study in the Netherlands. 557P. Abstract from Unknown event, Asilomar, USA.
Mantel-Teeuwisse, A. K., Klungel, O. H., Verschuren, W. M. M., Porsius, A. J., & de Boer, A. (2002). Patterns of lipid lowering drug use after withdrawal of cerivastatin. S68-S68. Abstract from Unknown event, Asilomar, USA.
2001
Scholarly publications
Mantel-Teeuwisse, A. K., Kloosterman, J. M., Maitland-van der Zee, A. H., Klungel, O. H., Porsius, A. J., & de Boer, A. (2001). Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Safety, 24(6), 443-56.
Mantel-Teeuwisse, A. K., Klungel, O. H., & de Boer, A. (2001). Lipid abnormalities induced by novel antipsychotic drugs. Drug Safety, 24(13), 1017-1018. [Repository]
Mantel-Teeuwisse, A. K., Klungel, O. H., Verschuren, W. M., Porsius, A., & de Boer, A. (2001). Comparison of different methods to estimate prevalence of drug use by using pharmacy records. Journal of Clinical Epidemiology, 54(11), 1181-1186.
Mantel-Teeuwisse, A. K., Kloosterman, J. M. E., Maitland-van der Zee, A. H., Klungel, O. H., Porsius, A. J., & de Boer, A. (2001). Drug-Induces Lipid Changes. Drug Safety, 24(6), 443-456.
Other output
Mantel-Teeuwisse, A. K., Klungel, O. H., Verschuren, W. M. M., Porsius, A. J., & de Boer, A. (2001). Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminatied. S72-S72. Abstract from Unknown event, Asilomar, USA.
Mantel-Teeuwisse, A. K., Lindemans, A. D., Verschuren, W. M. M., Klungel, O. H., Porsius, A. J., & de Boer, A. (2001). Undertreatment of hypercholesterolemia in a population-based study in The Netherlands. S73-S73. Abstract from Unknown event, Asilomar, USA.
2000
Scholarly publications
Teeuwisse, A., Klungel, O., Porsius, A., & De Boer, A. (2000). Doelmatigheid van cholesterolverlagende geneesmiddelen. Pharmaceutisch Weekblad, 135(4), 106.
Professional publications
Mantel-Teeuwisse, A. K., Klungel, O. H., Porsius, A. J., & de Boer, A. (2000). Cholesterolverlagers en doelmatigheid. Pharmaceutisch Weekblad, 135(4), 108.
Other output
Mantel-Teeuwisse, A. K. (2000). Vergelijking van verschillende methodes om prevalentie van geneesmiddelgebruik te schatten met behulp van apotheekgegevens. 46-46. Abstract from Unknown event, Asilomar, USA.
Mantel-Teeuwisse, A. K., Klungel, O. H., Verschuren, W. M. M., Porsius, A. J., & de Boer, A. (2000). Comparison of different methods to estimate prevalence of drug use by using pharmacy records. S1-S1. Abstract from Unknown event, Asilomar, USA.
Mantel-Teeuwisse, A. K. (2000). Estimation of prevalence of cholesterol lowering drug use in the general Dutch population. 384P-384P. Abstract from Unknown event, Asilomar, USA.
1999
Scholarly publications
Teeuwisse, A. K., Porsius, A. J., & De Boer, A. (1999). Kwaliteit von behandeling von patienten met hypercholesterolemie: De weerbarstige praktijk. Pharmaceutisch Weekblad, 134(48), 1680-1683.
Professional publications
De Boer, A., Peterse, E. E. M., Teeuwisse, A. K., & Porsius, A. J. (1999). Farmacotherapie van hyperlipidemie. Pharmaceutisch Weekblad, 134(48), 1667-1671.
de Boer, A., Peterse, E. E. M., Mantel-Teeuwisse, A. K., & Porsius, A. J. (1999). De medicamenteuze behandeling van hyperlipidemie. Pharmaceutisch Weekblad, 134(48), 1667-1671.
Mantel-Teeuwisse, A. K., Porsius, A. J., & de Boer, A. (1999). Kwaliteit van behandeling van patiënten met hypercholesterolemie. Pharmaceutisch Weekblad, 134(48), 1680-1683.